Methods and Compositions for Cannabinoid-Based Therapeutics

Abstract

The present disclosure provides methods and systems for forming a combination therapeutic composition. The combination therapeutic composition may include a cannabinoid compound and a non-cannabinoid therapeutic compound. The combination therapeutic composition may include a plurality of stable droplets as part of an emulsion. The combination therapeutic composition may be present in other dosage forms, such as a solid dosage form (e.g., a tablet). In one embodiment, at least one of i) the cannabinoid compound and ii) the non-cannabinoid therapeutic compound is encapsulated.

Description

Technical Field

[0001] Cross-reference This application claims priority based on U.S. Provisional Patent Application No. 63 / 119,842 filed on December 1, 2020 and U.S. Provisional Patent Application No. 63 / 119,862 filed on December 1, 2020, and these provisional applications are incorporated herein by reference in their entirety for reference.

Background Art

[0002] Background Therapeutic compositions have the drawback that their utility for administration to a subject is limited. Many compositions are destroyed, degraded, or removed by the liver, reducing delivery to the subject. Many therapeutic compositions also have low bioavailability and storage stability.

Summary of the Invention

Means for Solving the Problems

[0003] Abstract There is a substantial need for compositions having increased bioavailability, increased storage stability, reduced first-pass metabolism, and other beneficial properties. Methods are provided for incorporating a therapeutic compound into a composition to increase bioavailability, increase storage stability, reduce first-pass metabolism, extend or modify the release profile, or increase solubility in water, for example to facilitate its delivery and / or administration to a subject. The therapeutic compositions of the present disclosure can be used to treat various diseases or conditions in a subject. In some embodiments, microencapsulation can include generating a plurality of droplets in an emulsion.

[0004] In one embodiment, the present disclosure provides a composition comprising a cannabinoid compound and a non-cannabinoid therapeutic compound, wherein the non-cannabinoid therapeutic compound is selected from the group consisting of Kyprolis, Epogen, Nplate, Vectibix, Blincyto, Corlanor, Evenity, Imlygic, Kanjinti, MVASI, Neupogen, Prolia, Repatha, Depakote, Gengraf, Kaletra, Leuplin, Mavyret, Oriahn, Rinvoq, Survanta, Synthroid, ultane, venclexta, viekira, zemplar, Triumeq, Keytruda, Gardasil, Pneumovax, Ocrevus, Cyramza, doxorubicin, doxorubicin in nanoinducible liposomes, taxanes in nanoinducible liposomes, ketamine, statins, dextromethorphan, nonsteroidal anti-inflammatory drugs, benzodiazepines, and Tables 1 to 10.

[0005] In one embodiment, at least one of i) the cannabinoid compound and ii) the non-cannabinoid therapeutic compound is encapsulated.

[0006] In one embodiment, the non-cannabinoid therapeutic compound is doxorubicin.

[0007] In one embodiment, the non-cannabinoid therapeutic compound is doxorubicin in nano-inducible liposomes.

[0008] In one embodiment, the non-cannabinoid therapeutic compound is the taxane of the nanoinducible liposome.

[0009] In one embodiment, the non-cannabinoid therapeutic compound is ketamine.

[0010] In one embodiment, the non-cannabinoid therapeutic compound is a statin.

[0011] In one embodiment, the statin is atorvastatin.

[0012] In one embodiment, the statin is fluvastatin.

[0013] In one embodiment, the statin is lovastatin.

[0014] In one embodiment, the non-cannabinoid therapeutic compound is dextromethorphan.

[0015] In one embodiment, the non-cannabinoid therapeutic compound is a nonsteroidal anti-inflammatory drug.

[0016] In one embodiment, the nonsteroidal anti-inflammatory drug is ibuprofen.

[0017] In one embodiment, the nonsteroidal anti-inflammatory drug is acetaminophen.

[0018] In one embodiment, the nonsteroidal anti-inflammatory drug is naproxen.

[0019] In one embodiment, the non-cannabinoid therapeutic compound is a benzodiazepine.

[0020] In one embodiment, the benzodiazepine is diazepam.

[0021] In one embodiment, the benzodiazepine is alprazolam.

[0022] In one embodiment, the benzodiazepine is clonazepam.

[0023] In one embodiment, the benzodiazepine is temazepam.

[0024] In one embodiment, the cannabinoid compound is encapsulated.

[0025] In one embodiment, the non-cannabinoid therapeutic compound is encapsulated.

[0026] In one embodiment, the cannabinoid compound and the non-cannabinoid therapeutic compound are encapsulated.

[0027] In one embodiment, the cannabinoid compound and the non-cannabinoid therapeutic compound are encapsulated in the same microcapsule of the plurality of microcapsules of the composition.

[0028] In one embodiment, the cannabinoid compound and the non-cannabinoid therapeutic compound are encapsulated in different microcapsules of the plurality of microcapsules of the composition.

[0029] In one embodiment, the composition is in a solid dosage form.

[0030] In one embodiment, the solid dosage form includes one or more members selected from the group consisting of pills, tablets, powders, capsules, and granules.

[0031] In one embodiment, the cannabinoid compound and the non-cannabinoid therapeutic compound are present in the same solid dosage form.

[0032] In one embodiment, the cannabinoid compound and the non-cannabinoid therapeutic compound are present in different solid dosage forms.

[0033] In one embodiment, the composition includes a first unit dosage form containing the cannabinoid compound and a second unit dosage form containing the non-cannabinoid therapeutic compound, and the first unit dosage form and the second unit dosage form are for sequential or simultaneous administration to a subject in need thereof.

[0034] In one embodiment, the composition can synergistically provide a higher degree of therapeutic efficacy in the target population compared to either the cannabinoid compound or the non-cannabinoid therapeutic compound alone.

[0035] In another embodiment, the Disclosure provides a kit comprising one of the preceding embodiments of the composition, further comprising instructions for administering the composition to a subject requiring it.

[0036] In another embodiment, the present disclosure provides a method comprising the step of administering one of the compositions of the prior embodiments to a subject requiring it.

[0037] In one embodiment, the cannabinoid targets the endogenous cannabinoid system.

[0038] In one embodiment, administration of the composition results in one or more effects from the group consisting of an improved therapeutic range, reduced toxicity, reduced side effects, enhanced therapeutic effect, and enhancement of overall homeostasis by improving homeostasis in the target cells, organs, or systemic tissues.

[0039] The best way to get it is with a snowflake and a snowflake Thanks for reading the snowflakes Drug Enbrel, Neulasta, Prolia, XGEVA, Aranesp, Sensipar / Mimpara, Avs wave, Otezla, Parsabiv, AndroGel, Creon, Duopa, Humira, Imbruvica, Niaspan, Orilissa, Skyrizi, Synagis, Trilipix, Advair, Tivicay, Breo / Relvar Ellipta, Ventolin, Lamictal, Avodart, Flovent, Augmentin, Rotarix, Shingrix, Januvia, Janumet, Isentress, Bridion uvaRing、Simponi、Zetia / Vytorin、Herceptin、Avastin、Rituxan、Perjeta、Xolair、Actemra、Lucentis、Activase / TNKase、E sbriet, Lantus, Aubagio, Lovenox, Plavix, Myozyme, Toujeo, Dupixent, Fabrazyme, Trulicity, Humalog, Alimta, Cialis, F orteo、Humulin、Taltz、Basaglar、Cymbalta、Xarelto、Eylea、Mirena、Kogenate、Nexavar、Yasmin、Precose、Adalat、Aspirin Cardio, Betaseron, Tagrisso, Symbicort, Brilinta, Farxiga, Nexium, Imfinzi, Pulmicort, Crestor, Lynparza, Faslodex, Eliquis, Opdivo, Sprycel, Orencia SC、Yervoy、Orencia、Revlimid、Baraclude、Empliciti、Nulojix、Stelara、Remicade、Zytiga、Invega Sustenna、Darzalex、Prezista、Imbruvica、Opsumit、Prevnar13, Lyrica, Ibrance, Lipitor, Xeljanz, Chantix, Sutent, Norvasc, Premarin, Gilenya, Cosentyx, Lucentis, Tasigna, Sandostatin, Gleevec, Afinitor, Galvus, Promacta, Tafinlar, Entyvio , Velcade, Leuprorelin, Azilva, Dexilant, Ninlaro, Genvoya, Truvada, Epclusa, Odefsey, Descovy, Harvoni, Atripla, Biktarvy, Letairis, Ranexa, Copaxone, Bendeka, Methylphenidate Hydrochloride, ProAir HFA, Austedo, QVAR The present invention provides a composition selected from the group consisting of RediHaler, daptomycin, metoprolol succinate, sildenafil citrate, hypochlorous acid, doxorubicin, nanoinducible liposome doxorubicin, nanoinducible liposome taxane, ketamine, statin, dextromethorphan, nonsteroidal anti-inflammatory drugs, and benzodiazepines.

[0040] In one embodiment, at least one of i) the cannabinoid compound and ii) the non-cannabinoid therapeutic compound is encapsulated.

[0041] In one embodiment, the non-cannabinoid therapeutic compound is doxorubicin.

[0042] In one embodiment, the non-cannabinoid therapeutic compound is doxorubicin in nano-inducible liposomes.

[0043] In one embodiment, the non-cannabinoid therapeutic compound is a taxane of nanoinducible liposomes.

[0044] In one embodiment, the non-cannabinoid therapeutic compound is ketamine.

[0045] In one embodiment, the non-cannabinoid therapeutic compound is a statin.

[0046] In one embodiment, the statin is atorvastatin.

[0047] In one embodiment, the statin is fluvastatin.

[0048] In one embodiment, the statin is lovastatin.

[0049] In one embodiment, the non-cannabinoid therapeutic compound is dextromethorphan.

[0050] In one embodiment, the non-cannabinoid therapeutic compound is a nonsteroidal anti-inflammatory drug.

[0051] In one embodiment, the nonsteroidal anti-inflammatory drug is ibuprofen.

[0052] In one embodiment, the nonsteroidal anti-inflammatory drug is acetaminophen.

[0053] In one embodiment, the nonsteroidal anti-inflammatory drug is naproxen.

[0054] In one embodiment, the non-cannabinoid therapeutic compound is a benzodiazepine.

[0055] In one embodiment, the benzodiazepine is diazepam.

[0056] In one embodiment, the benzodiazepine is alprazolam.

[0057] In one embodiment, the benzodiazepine is clonazepam.

[0058] In one embodiment, the benzodiazepine is temazepam.

[0059] In one embodiment, the cannabinoid compound is encapsulated.

[0060] In one embodiment, the non-cannabinoid therapeutic compound is encapsulated.

[0061] In one embodiment, the cannabinoid compound and the non-cannabinoid therapeutic compound are encapsulated.

[0062] In one embodiment, the cannabinoid compound and the non-cannabinoid therapeutic compound are encapsulated in the same microcapsules of a plurality of microcapsules of the composition.

[0063] In one embodiment, the cannabinoid compound and the non-cannabinoid therapeutic compound are encapsulated in different microcapsules of a plurality of microcapsules of the composition.

[0064] In one embodiment, the composition is in solid dosage form.

[0065] In one embodiment, the solid dosage form includes one or more members selected from the group consisting of pills, tablets, powders, capsules, and granules.

[0066] In one embodiment, the cannabinoid compound and the non-cannabinoid therapeutic compound are present in the same solid dosage form.

[0067] In one embodiment, the cannabinoid compound and the non-cannabinoid therapeutic compound are present in different solid dosage forms.

[0068] In one embodiment, the composition comprises a first unit dosage form containing the cannabinoid compound and a second unit dosage form containing the non-cannabinoid therapeutic compound, wherein the first unit dosage form and the second unit dosage form are intended to be administered sequentially or simultaneously to a subject requiring them.

[0069] In one embodiment, the composition can synergistically provide a higher degree of therapeutic efficacy in the target population compared to either the cannabinoid compound or the non-cannabinoid therapeutic compound alone.

[0070] In another embodiment, the Disclosure provides a kit comprising one of the preceding embodiments of the composition, further comprising instructions for administering the composition to a subject requiring it.

[0071] In another embodiment, the present disclosure provides a method comprising the step of administering one of the compositions of the prior embodiments to a subject requiring it.

[0072] In one embodiment, cannabinoids target the endogenous cannabinoid system.

[0073] In one embodiment, administration of the composition results in one or more effects from the group consisting of an improved therapeutic range, reduced toxicity, reduced side effects, enhanced therapeutic effect, and enhancement of overall homeostasis by improving homeostasis in the target cells, organs, or systemic tissues.

[0074] In another embodiment, the Disclosure relates to a method comprising the step of administering a composition comprising a cannabinoid compound and a non-cannabinoid therapeutic compound to a subject in need thereof, wherein the non-cannabinoid therapeutic compound is Kyprolis, Epogen, Nplate, Vectibix, Blincyto, Corlanor, Evenity, Imlygic, Kanjinti, MVASI, Neupogen, Prolia, Repatha, Depakote, Gengraf, Kaletra, Leuplin, Mavy The present invention provides a method using ret, Oriahn, Rinvoq, Survanta, Synthroid, ultane, venclexta, viekira, zemplar, Triumeq, Keytruda, Gardasil, Pneumovax, Ocrevus, Cyramza, doxorubicin, doxorubicin in nano-inducible liposomes, taxanes in nano-inducible liposomes, ketamine, statins, dextromethorphan, nonsteroidal anti-inflammatory drugs, benzodiazepines, and a method selected from the group consisting of Tables 1-10.

[0075] The best way to do this is to have a smooth, smooth surface The slightly less expensive snowflakes are available and you can choose from them Features Enbrel, Neulasta, Prolia, XGEVA, Aranesp, Sensipar / Mi mpara, Aranesp, Avsola, Otezla, Parsabiv, AndroGel, Creon, Duopa, Humira, Imbruv ica, Niaspan, Orilissa, Skyrizi, Synagis, Trilipix, Advair, Tivicay, Breo / Relvar Ellipta, Ventolin, Lamictal, Avodart, Flovent, Augmentin, Rotarix, Shingrix, Januvia, Janumet, Isentress, Bridion uvaRing、Simponi、Zetia / Vytorin、Herceptin、Avastin、Rituxan、Perjeta、Xolair、Actemra、Lucentis、Activase / TNKase、 Esbriet, Lantus, Aubagio, Lovenox, Plavix, Myozyme, Toujeo, Dupixent, Fabrazyme, Trulicity, Humalog, Alimta, Cialis. Forteo、Humulin、Taltz、Basaglar、Cymbalta、Xarelto、Eylea、Mirena、Kogenate、Nexavar、Yasmin、Precose、Adalat、Asprin Cardio, Betaseron, Tagrisso, Symbicort, Brilinta, Farxiga, Nexium, Imfinzi, Pulmicort, Crestor, Lynparza, Faslodex, Eliquis, Opdivo, Sprycel, Orencia SC, Yervoy, Orencia, Revlimid, Baraclude, Empliciti, Nulojix, Stelara, Remicade, Zytiga, Xarelto, Invega Sustenna、Simponi、Darzalex、Prezista、Imbruvica、Opsumit、Prevnar13, Lyrica, Ibrance, Enbrel, Lipitor, Xeljanz, Chantix, Sutent, Norvasc, Premarin, Gilenya, Cosentyx, Lucentis, Tasigna, Sandostatin, Gleevec, Afinitor, Galvus, Promacta, Tafinlar, Enty vio, Velcade, Leuprorelin, Azilva, Dexilant, Ninlaro, Genvoya, Truvada, Epclusa, Odefsey, Descovy, Harvoni, Atripla, Biktarvy, Letairis, Ranexa, Copaxone, Bendeka, Methylphenidate Hydrochloride, ProAir HFA, Austedo, Methylphenidate Hydrochloride, QVAR The present invention provides a method selected from the group consisting of RediHaler, daptomycin, metoprolol succinate, sildenafil citrate, hypochlorite, doxorubicin, doxorubicin in nanoinducible liposomes, taxanes in nanoinducible liposomes, ketamine, statins, dextromethorphan, nonsteroidal anti-inflammatory drugs, and benzodiazepines.

[0076] Further aspects and advantages of the present disclosure will be readily apparent to those skilled in the art from the following detailed description, which only illustrates the exemplary embodiments of the present disclosure. As will be recognized, other different embodiments are possible, and some of their details can be modified in various obvious ways, all without departing from the present disclosure. Accordingly, the drawings and description should be considered illustrative and not limiting.

[0077] Reference All publications, patents, and patent applications cited herein are incorporated by reference to the same extent that each individual publication, patent, or patent application is specifically and individually indicated as being incorporated by reference. To the extent that any publications and patents or patent applications incorporated by reference conflict with any disclosures contained herein, this Specified is intended to take precedence and / or supersede any such conflicting material. [Brief explanation of the drawing]

[0078] Novel features of the present invention are presented in detail in the appended claims. A better understanding of the features and advantages of this disclosure will be obtained by referring to the following detailed description of exemplary embodiments in which the principles of the present invention are utilized, and by referring to the accompanying drawings or images (also referred to herein as "Fig." and "Figs.").

[0079] [Figure 1A] Figure 1A shows an example of a droplet generator.

[0080] [Figure 1B] Figure 1B shows another example of a droplet generator.

[0081] [Figure 1C] Figure 1C shows an example of a microfluidic structure.

[0082] [Figure 2A] Figure 2A shows an exemplary microscopic image at 400x magnification of the raw composition of quillaja extract, hemp oil, and water.

[0083] [Figure 2B] Figure 2B shows an exemplary microscopic image at 1000x magnification of the raw composition of quillaja extract, hemp oil, and water.

[0084] [Figure 3A]Figure 3A shows an exemplary microscopic image at 400x magnification of a microfluidically processed composition of quillaja extract, hemp oil, and water.

[0085] [Figure 3B] Figure 3B shows an exemplary microscopic image at 400x magnification of a microfluidically processed composition of quillaja extract, hemp oil, and water.

[0086] [Figure 3C] Figure 3C shows an exemplary microscopic image at 1000x magnification of a microfluidically processed composition of quillaja extract, hemp oil, and water.

[0087] [Figure 3D] Figure 3D shows an exemplary microscopic image at 1000x magnification of a microfluidically processed composition of quillaja extract, hemp oil, and water.

[0088] [Figure 4A] Figure 4A shows exemplary microscopic images at 1000x magnification of a microfluidically processed composition of quillaja extract, cannabis oil, water, and sodium alginate.

[0089] [Figure 4B] Figure 4B shows exemplary microscopic images at 1000x magnification of a microfluidically processed composition of quillaja extract, cannabis oil, water, and sodium alginate.

[0090] [Figure 4C] Figure 4C shows exemplary microscopic images at 1000x magnification of a microfluidically processed composition of quillaja extract, cannabis oil, water, and sodium alginate.

[0091] [Figures 5A-5D] Figures 5A to 5D show examples of tablets containing the therapeutic compositions disclosed herein.

[0092] [Figures 6A-6D]Figures 6A to 6D show examples of pills containing therapeutic compositions disclosed herein. [Modes for carrying out the invention]

[0093] (Detailed explanation) Preferred embodiments of the present invention are illustrated and described herein, but it will be apparent to those skilled in the art that such embodiments are presented merely as examples. Numerous variations, modifications, and substitutions can be conceived by those skilled in the art without departing from the present invention. It should be understood that various alternative forms to the embodiments of the present invention described herein may be adopted.

[0094] The terms “about” or “near” as used herein generally refer to within + / - 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of the specified amount.

[0095] The terms “subject” or “individual,” as used herein, generally refer to vertebrates such as mammals. A subject may be a patient. Mammals may include, but are not limited to, mice, monkeys, humans, domestic animals, sports animals, and pets. Tissues, cells, and their offspring of biological entities obtained in vivo or cultured in vitro are also included.

[0096] The term “treatment” or “to treat” generally refers to an approach to obtain a beneficial or desired outcome, including but not limited to therapeutic benefits. Therapeutic benefits may include preventive benefits. For example, treatment may include administering one of the compositions disclosed herein (e.g., therapeutic compositions). A therapeutic benefit means any improvement in or effect on one or more diseases, conditions, or symptoms associated with treatment under treatment. For preventive benefits, a composition may be administered to a person at risk of developing a particular disease, condition, or symptom, or to a person who has reported one or more physiological symptoms of a disease, even though the disease, condition, or symptom has not yet manifested.

[0097] The terms “remission of a condition” or “remission of a subject” generally refer to a reduction in the effect or manifestation of a disease, illness, condition, or medical problem or condition. Remission of a subject can refer to the remission of one or more conditions of a subject. Remission of a condition can refer to a reduction in the negative characteristics of a subject or condition.

[0098] The terms “effective dose” or “therapeutic dose” generally refer to an amount of the composition disclosed herein that is sufficient to produce the desired activity when administered to a subject in need of it. In some cases, the term “therapeutically effective” may refer to an amount of the composition sufficient to delay the onset, inhibit the progression of, alleviate, or reduce at least one symptom of a disorder treated by the composition or method disclosed herein.

[0099] This disclosure provides therapeutic compositions comprising several different therapeutic drugs or compounds, as well as methods for the manufacture, delivery, and use of such compositions. A combination of several different therapeutic drugs (i.e., combination therapy) can synergistically produce a higher degree of efficacy (e.g., therapeutic efficacy in the subject requiring it) compared to any one of several different therapeutic drugs alone. A combination of several different therapeutic drugs (e.g., into a single composition) can facilitate enhanced medication adherence or compliance by the subject requiring it compared to having to take several different therapeutic drugs separately. In some embodiments, the composition may include a first therapeutic compound (e.g., a cannabinoid compound) and a second therapeutic compound (e.g., a non-cannabinoid therapeutic compound) different from the first therapeutic compound. The composition may be in the form of a liquid, a solid (e.g., pills, tablets, powders, capsules, granules, etc.), a semi-solid (e.g., a gel), or a mixture thereof.

[0100] In one embodiment, the composition may include a first composition comprising a first therapeutic compound (e.g., a cannabinoid compound) and a second composition comprising a second therapeutic compound (e.g., a non-cannabinoid therapeutic compound). The first and second compositions may exist in the same unit dose (e.g., the same unit dosage form). Alternatively, the first and second compositions may exist in different unit doses (e.g., different unit dosage forms).

[0101] In one embodiment, the composition may be a solid composition (e.g., pills, tablets, powders, capsules, granules, etc.). The solid composition may contain a plurality of first therapeutic compounds (e.g., cannabinoid compounds) and a plurality of second therapeutic compounds (e.g., non-cannabinoid therapeutic compounds).

[0102] In some cases, multiple first therapeutic compounds and multiple second therapeutic compounds may be mixed in a solid composition (e.g., a homogeneous mixture, a heterogeneous or non-uniform mixture).

[0103] In some cases, the multiple first therapeutic compounds and the multiple second therapeutic compounds do not need to be mixed. The multiple first therapeutic compounds and the multiple second therapeutic compounds may be present in different parts of the solid composition. For example, (1) one of the multiple first therapeutic compounds and the multiple second therapeutic compounds may be present in the core of the solid composition, and (2) the other of the multiple first therapeutic compounds and the multiple second therapeutic compounds may be present in the outer layer (e.g., shell) of the core of the solid composition. In another example, the solid composition may consist of multiple layers, where (1) one of the multiple first therapeutic compounds and the multiple second therapeutic compounds may be present in the first layer of the multiple layers, and (2) the other of the multiple first therapeutic compounds and the multiple second therapeutic compounds may be present in the second layer of the multiple layers. The first and second layers may be adjacent to each other. Alternatively, the first and second layers may be separated by at least a third layer and different layers of the multiple layers.

[0104] The different stereostructures of multiple first and multiple second therapeutic compounds in a solid composition can provide benefits such as storage stability, improved bioavailability, reduced first-pass metabolism, and extended or modified release profiles (e.g., a first release profile for the first drug and a second release profile for the second drug that differs from the first release profile).

[0105] In one embodiment, the Disclosure provides encapsulation of therapeutic compositions disclosed herein, as well as methods for the manufacture, delivery, and use of such compositions. At least a portion of a therapeutic composition may be encapsulated in a microcapsule, including within a microcapsule. Microencapsulation can provide benefits such as storage stability, improved bioavailability, reduced first-pass metabolism, and extended or modified release profiles (e.g., a first release profile for a first drug, and a second release profile for a second drug that differs from the first release profile). Microencapsulation may involve generating multiple droplets in an emulsion. Microencapsulation can increase the solubility of a therapeutic composition in water (e.g., the solubility of an oil-based therapeutic composition) to facilitate, for example, the delivery and / or administration of the therapeutic composition to a subject. The therapeutic compositions of the Disclosure may include cannabinoids, terpenes, essential oils, and other desirable compounds (e.g., non-cannabinoid therapeutic compounds).

[0106] In one embodiment, the present disclosure provides a composition comprising a plurality of microcapsules, wherein each of the plurality of microcapsules comprises one or more therapeutic compositions present in an amount of at least about 1 microgram.

[0107] In some cases, individual microcapsules of a plurality of microcapsules may contain multiple different therapeutic compounds (e.g., cannabinoid compounds and non-cannabinoid therapeutic compounds). In other cases, a first individual microcapsule of a plurality of microcapsules may contain a first therapeutic compound (e.g., a cannabinoid compound), and a second individual microcapsule of a plurality of microcapsules may contain a second therapeutic compound (e.g., a non-cannabinoid therapeutic compound).

[0108] In some cases, individual microcapsules of a plurality of microcapsules in a composition may contain a cannabinoid compound (i.e., an encapsulated cannabinoid compound), and the composition may further contain different unencapsulated therapeutic compounds (e.g., non-cannabinoid therapeutic compounds). In other cases, individual microcapsules of a plurality of microcapsules in a composition may contain a non-cannabinoid therapeutic compound (i.e., an encapsulated non-cannabinoid therapeutic compound), and the composition may further contain unencapsulated cannabinoid compounds.

[0109] In some cases, each individual microcapsule of a group of microcapsules may contain (i) a first therapeutic compound (e.g., a cannabinoid compound) that is encapsulated, and (ii) a second therapeutic compound (e.g., a non-cannabinoid therapeutic compound) that is positioned on the surface of the individual microcapsule (e.g., outer surface, inner surface). In some examples, each individual microcapsule may contain multiple amphiphilic molecules, and the second therapeutic compound may bind to the amphiphilic molecules of the multiple amphiphilic molecules (e.g., to the hydrophilic portion of the amphiphilic molecules or to the hydrophobic portion of the amphiphilic molecules). For example, the second therapeutic compound may bind to the outer surface of the individual microcapsule.

[0110] In some cases, individual microcapsules of a group of microcapsules may contain a non-cannabinoid therapeutic compound as an emulsifier. The non-cannabinoid therapeutic compound may be an amphiphilic molecule. Multiple such non-cannabinoid therapeutic compounds can be used to form multiple microcapsules, encapsulating one or more cannabinoid compounds.

[0111] In some embodiments, the non-cannabinoid therapeutic compounds disclosed herein may include non-terpene compounds.

[0112] Non-limiting examples of non-cannabinoid therapeutic compounds disclosed herein (with applicable therapeutic indications) include KYPROLIS (or carfilzomib) (e.g., for multiple myeloma), EPOGEN (or epoetin alfa) (e.g., for anemia), Nplate (or romiplostim) (e.g., for immune thromboytopenia), Vectibix (or panitumumab) (e.g., for colorectal cancer), Blincyto (or blinatumomab) (e.g., for cancer, e.g., acute lymphoblastic leukemia (ALL)), Corlanor (or ivabradine) (e.g., for cardiac conditions, e.g., heart failure), Ev This may include enity (or romosozumab-aqqg) (e.g., in postmenopausal women, e.g., for osteoporosis), Imlygic (or tarimodine laherpalepvec) (e.g., for melanoma), Kanjinti (or trastuzumab-anns) (e.g., for cancer), MVASI (or bevacizumab) (e.g., for cancer, e.g., certain colorectal, lung, brain, kidney, and cervical cancer), Neupogen (or filgrastim) (e.g., for cancer), Prolia (or denosumab) (e.g., for osteoporosis), and Repatha (or evolocumab) (e.g., for cardiac conditions, e.g., for heart attack, stroke, etc.).

[0113] Non-limiting examples of non-cannabinoid therapeutic compounds disclosed herein (with applicable therapeutic indications) include Enbrel (or etanercept) (e.g., for rheumatoid arthritis), Neulasta (or filgrastim) (e.g., for chemotherapy), Prolia (or denosumab) (e.g., for bone cancer, e.g., osteosarcoma), XGEVA (or denosumab) (e.g., for bone cancer, e.g., osteosarcoma), Aranesp (or darbepoetin alfa). This may include (for example, for chemotherapy), Sensipar / Mimpara (or cinacalcet) (for example, for renal disease), Aranesp (or darbepoetin alfa) (for example, for anemia), Avsola (or infliximab-axxq) (for example, for arthritis), Otezla (or apremilast) (for example, for severe plaque psoriasis), and Parsabiv (or etelcalcetide) (for example, for secondary hyperparathyroidism).

[0114] Non-limiting further examples of non-cannabinoid therapeutic compounds disclosed herein (with applicable therapeutic indications) include AndroGel (or testosterone gel) (e.g., for boosting testosterone), Creon (or pancrelipase) (e.g., for cystic fibrosis), Duopa or (carbidopa / levodopa) (e.g., for Parkinson's disease), Humira (or adalimumab) (e.g., for Crohn's disease, psoriasis vulgaris, rheumatoid arthritis), and Imbruvica (ibrutinib). These may include (for example, for chronic lymphocytic leukemia), Niaspan (or niacin) (for example, for cholesterol treatment), Orilissa (or elagolyx) (for example, for pain associated with endometriosis), Skyrizi (or risankizumab-rzaa) (for example, for psoriasis vulgaris), Synagis (or palivizumab) (for example, for respiratory syncytial virus (RSV)), and Trilipix (or fenofibric acid) (for example, for high cholesterol).

[0115] Non-limiting further examples of non-cannabinoid therapeutic compounds disclosed herein (with applicable therapeutic indications) include: Advair (or fluticasone propionate / salmeterol) (e.g., for the treatment of asthma and chronic obstructive pulmonary disease (COPD)), Tivicay (or dolutegravir) (e.g., for antiretroviral therapy, e.g., for HIV treatment), Breo / Relvar Ellipta (or fluticasone furoate and vilanterol) (e.g., for the treatment of chronic obstructive pulmonary disease (COPD)), Ventolin (or albuterol) (e.g., for the prevention and / or treatment of wheezing and shortness of breath caused by respiratory problems (e.g., asthma, chronic obstructive pulmonary disease)), Lamictal (or lamotrigine) (e.g., for the prevention and / or control of seizures, mood swings in bipolar disorder in adults, etc.), Avodart (or dutasteride) (e.g., symptoms of benign prostatic hyperplasia (i.e., benign prostatic hyperplasia)). This may include medications for treating hypertrophic hypertrophy (BPH), Flovent (or fluticasone propionate) (e.g., for treating asthma in patients aged 4 years and older), Augmentin (or amoxicillin / clavulanate) (e.g., for treating bacterial infections), Rotarix (or attenuated live human rotavirus (HRV) strains) (e.g., for the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types), and Shingrix (or recombinant herpes zoster vaccine) (e.g., for the prevention of herpes zoster).

[0116] Non-limiting further examples of non-cannabinoid therapeutic compounds disclosed herein (with applicable therapeutic indications) include: Advair (or fluticasone propionate / salmeterol) (e.g., for the treatment of asthma and chronic obstructive pulmonary disease (COPD)), Tivicay (or dolutegravir) (e.g., for antiretroviral therapy, e.g., for HIV treatment), Breo / Relvar Ellipta (or fluticasone furoate and vilanterol) (e.g., for the treatment of chronic obstructive pulmonary disease (COPD)), Ventolin (or albuterol) (e.g., for the prevention and / or treatment of wheezing and shortness of breath caused by respiratory problems (e.g., asthma, chronic obstructive pulmonary disease)), Lamictal (or lamotrigine) (e.g., for the prevention and / or control of seizures, mood swings in bipolar disorder in adults, etc.), Avodart (or dutasteride) (e.g., symptoms of benign prostatic hyperplasia (i.e., benign prostatic hyperplasia)). This may include medications for treating hypertrophic hypertrophy (BPH), Flovent (or fluticasone propionate) (e.g., for treating asthma in patients aged 4 years and older), Augmentin (or amoxicillin / clavulanate) (e.g., for treating bacterial infections), Rotarix (or attenuated live human rotavirus (HRV) strains) (e.g., for the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types), and Shingrix (or recombinant herpes zoster vaccine) (e.g., for the prevention of herpes zoster).

[0117] Non-limiting further examples of non-cannabinoid therapeutic compounds disclosed herein (with applicable therapeutic indications) include: Depakote (or divalproex sodium) (e.g., for bipolar disorder), Gengraf (or cyclosporine) (e.g., for preventing or reducing organ rejection in subjects who have undergone tissue transplantation, e.g., liver, kidney, or heart transplantation), Kaletra (or lopinavir / ritonavir) (e.g., for HIV), Leuplin (or leuprolide hormone) (e.g., for prostate cancer), Mavyret (or glecaprevir / pibrentasvir) (e.g., for hepatitis C), Oriahn (or combination of estrogen and progestin) (e.g., for menstrual bleeding related to uterine fibroids in premenopausal women). These may include blood-related ointments, Rinvoq (or upadacitinib) (e.g., for rheumatoid arthritis), Survanta (or belactant) (e.g., for respiratory distress syndrome (RDS)), Synthroid (or levothyroxine) (e.g., for hyperthyroidism), ultane (or sevoflurane) (e.g., for anesthetics), venclexta (or venetoclax) (e.g., for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)), viekira (or a fixed-dose combination of ombitasvir, paritaprevir, and ritonavir) (e.g., for hepatitis C virus (HCV)), and zemplar (or paricalcitol) (e.g., for the prevention or treatment of secondary hyperparathyroidism).

[0118] Non-limiting further examples of non-cannabinoid therapeutic compounds (having applicable therapeutic indications) disclosed herein may include Triumeq (or a combination of abacavir, dolutegravir, and lamivudine) (for example, for HIV).

[0119] Non-limiting further examples of non-cannabinoid therapeutic compounds disclosed herein (with applicable therapeutic applications) may include Januvia (or sitagliptin) (e.g., for the treatment of type 2 diabetes), Janumet (or sitagliptin / metformin) (e.g., for diabetes and obesity), Isentress (or raltegravir) (e.g., for HIV / AIDS), Bridion (or sugammadex) (e.g., for recovery from anesthesia), the active compound in NuvaRing (or etonogestrel / ethinylestradiol) (e.g., for contraception), Simponi (or golimumab) (e.g., for rheumatoid arthritis), and Zetia / Vytorin (or ezetimibe / simvastatin) (e.g., for treating symptoms of high cholesterol and for lowering cholesterol).

[0120] Non-limiting further examples of non-cannabinoid therapeutic compounds disclosed herein (having applicable therapeutic indications) may include Keytruda (or pembrolizumab) (e.g., for non-small cell lung cancer (NSCLC), melanoma, classical Hodgkin lymphoma (cHL), urothelial carcinoma, head and neck squamous cell carcinoma (HNSCC), orgastroesophageal junction adenocarcinoma, and cancers with high microsatellite instability (MSI-H) or mismatch repair deficiency), Gardasil (or human papillomavirus (HPV) vaccine) (e.g., for HPV), and Pneumovax (or pneumococcal vaccine) (e.g., for pneumococcal disease).

[0121] Non-limiting further examples of non-cannabinoid therapeutic compounds (having applicable therapeutic indications) disclosed herein may include Ocrevus (or ocrelizumab) (for example, for relapsing-remitting MS (PRMS)).

[0122] Non-limiting further examples of non-cannabinoid therapeutic compounds disclosed herein (with applicable therapeutic indications) include Herceptin (or trastuzumab) (e.g., for cancer, e.g., breast cancer), Avastin (or bevacizumab) (e.g., for advanced colorectal, breast, lung, kidney, cervical and ovarian cancer, recurrent glioblastoma), Rituxan (or rituximab) (e.g., for hematological malignancies, rheumatoid arthritis, vasculitis), Perjeta This may include (or pertuzumab) (e.g., for breast cancer), Xolair (or omalizumab) (e.g., for asthma), Actemra (or tocilizumab) (e.g., for rheumatoid arthritis), Lucentis (or ranibizumab) (e.g., for macular degeneration), Activase / TNKase (or alteplase / tenecteplase) (e.g., for myocardial infarction), and Esbriet (or pirfenidone) (e.g., for pulmonary fibrosis).

[0123] Non-limiting further examples of non-cannabinoid therapeutic compounds (having applicable therapeutic indications) disclosed herein may include Cyramza (or ramucirumab) (for example, for cancer, e.g., gastric cancer).

[0124] Non-limiting further examples of non-cannabinoid therapeutic compounds disclosed herein (having applicable therapeutic indications) include Lantus (or insulin glargine) (e.g., for diabetes), Aubagio (or teriflunomide) (e.g., for relapsing-remitting MS (RRMS)), Lovenox (or enoxaparin sodium) (e.g., for thrombosis), Plavix (or clopidogrel) (e.g., for heart attack, stroke), Myozyme (or alglucosidase alfa) (e.g., for Pompe disease), Toujeo (or insulin glargine) (e.g., for diabetes), Dupixent (or dupilumab) (e.g., for eczema, dermatitis), and Fabrazyme (or agalsidase beta) (e.g., for Fabri disease).

[0125] Non-limiting further examples of non-cannabinoid therapeutic compounds disclosed herein (having applicable therapeutic indications) may include Trulicity (or dulaglutide) (e.g., for diabetes), Humalog (or insulin lispro) (e.g., for diabetes), Alimta (or pemetrexed) (e.g., for cancer), Cialis (or tadalafil) (e.g., for erectile dysfunction), Forteo (or teriparatide) (e.g., for osteoporosis), Humulin (or recombinant human insulin) (e.g., for diabetes), Taltz (or ixekizumab) (e.g., for psoriasis), Basaglar (or insulin glargine) (e.g., for diabetes), and Cymbalta (or duloxetine) (e.g., for anxiety, depression).

[0126] Non-limiting further examples of non-cannabinoid therapeutic compounds (with applicable therapeutic indications) disclosed herein may include one or more cancer drugs listed in Table 1. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5]

[0127] Non-limiting further examples of non-cannabinoid therapeutic compounds (having applicable therapeutic indications) disclosed herein may include Xarelto (or rivaroxaban) (e.g., for atrial fibrillation), Eylea (or aflibercept) (e.g., for macular degeneration), the active ingredient of Mirena (or levonorgestrel) (e.g., for contraception), Kogenate (or recombinant antihemophilic factor) (e.g., for hemophilia), Nexavar (or sorafenib) (e.g., for cancer), Yasmin (or drospirenone and ethinylestradiol) (e.g., for contraception), Precose (or acarbose) (e.g., for diabetes), Adalat (or nifedipine) (e.g., for hypertension), Aspirin Cardio (or aspirin or acetylsalicylic acid) (e.g., for the prevention of myocardial infarction), and Betaseron (or interferon beta-1b) (e.g., for multiple sclerosis).

[0128] Non-limiting further examples of non-cannabinoid therapeutic compounds (with applicable therapeutic indications) disclosed herein may include one or more benzodiazepines listed in Table 2. [Table 2]

[0129] Non-limiting further examples of non-cannabinoid therapeutic compounds disclosed herein (having applicable therapeutic indications) may include Tagrisso (or osimertinib) (e.g., for lung cancer), Symbicort (or budesonide / formoterol (Formotero)) (e.g., for asthma), Brilinta (or ticagrelor) (e.g., for antiplatelet effects), Farxiga (or dapagliflozin) (e.g., for type 2 diabetes), Nexium (or esomeprazole) (e.g., for acid reflux), Imfinzi (or durvalumab) (e.g., for bladder cancer), Pulmicort (or budesonide) (e.g., for asthma), Crestor (or rosuvastatin) (e.g., for cholesterol), Lynparza (or olaparib) (e.g., for fallopian tube cancer), and Faslodex (or fulvestrant) (e.g., for breast cancer).

[0130] Non-limiting further examples of non-cannabinoid therapeutic compounds (with applicable therapeutic indications) disclosed herein may include one or more opioids or opioid mimetic drugs listed in Table 3. [Table 3]

[0131] Non-limiting further examples of non-cannabinoid therapeutic compounds disclosed herein (with applicable therapeutic indications) include Eliquis (or apixaban) (e.g., for deep vein thrombosis and pulmonary embolism), Opdivo (or nivolumab) (e.g., for melanoma, lung cancer, and kidney cancer), Sprycel (or dasatinib) (e.g., for leukemia), and Orencia. This may include SC (or abatacept) (e.g., for rheumatoid arthritis), Yervoy (or ipilimumab) (e.g., for tumors), Orencia (or abatacept) (e.g., for rheumatoid arthritis), Revlimid (or lenalidomide) (e.g., for hepatitis B), Baraclude (or entecavir) (e.g., for HIV / AIDS), Empliciti (or elotuzumab) (e.g., for multiple myeloma), and Nulojix (or beratacept) (e.g., for kidney transplantation).

[0132] Non-limiting further examples of non-cannabinoid therapeutic compounds (with applicable therapeutic indications) disclosed herein may include one or more of the drugs listed in Table 4. [Table 4-1] [Table 4-2] [Table 4-3] [Table 4-4]

[0133] Non-limiting further examples of non-cannabinoid therapeutic compounds disclosed herein (having applicable therapeutic indications) may include Stellara (or ustekinumab) (e.g., for psoriasis), Remicade (or infliximab) (e.g., for rheumatoid arthritis), Zytiga (or abiraterone acetate) (e.g., for prostate cancer), Xarelto (or rivaroxaban) (e.g., for deep vein thrombosis, pulmonary embolism), Invega Sustenna (or paliperidone) (e.g., for schizophrenia), Simponi (or golimumab) (e.g., for rheumatoid arthritis), Darzalex (or daratumumab) (e.g., for multiple myeloma), Prezista (or darunavir) (e.g., for HIV / AIDS), Imbruvica (or ibrutinib) (e.g., for tumors), and Opsumit (or macitentan) (e.g., for hypertension).

[0134] Non-limiting further examples of non-cannabinoid therapeutic compounds (with applicable therapeutic indications) disclosed herein may include one or more generic drugs listed in Table 5. [Table 5]

[0135] Non-limiting further examples of non-cannabinoid therapeutic compounds disclosed herein (having applicable therapeutic indications) may include Prevnar 13 (or pneumococcal 13-valent conjugate vaccine) (e.g., for pneumococcal vaccines), Lyrica (or pregabalin) (e.g., for epilepsy, neuropathy), Ibrance (palbociclib) (e.g., for cancer), Enbrel (or etanercept) (e.g., for rheumatoid arthritis), Lipitor (or atorvastatin) (e.g., for cholesterol), Xeljanz (or tofacitinib) (e.g., for arthritis), Chantix (or varenicline) (e.g., for smoking cessation), Sutent (or sunitinib) (e.g., for cancer), Norvasc (or amlodipine) (e.g., for hypertension), and Premarin (or conjugated estrogen) (e.g., for menopause).

[0136] Non-limiting further examples of non-cannabinoid therapeutic compounds disclosed herein (with applicable therapeutic indications) include Gilenya (or fingolimod) (e.g., for autoimmune diseases), Cosentyx (or secukinumab) (e.g., for psoriasis, ankylosing spondylitis and psoriatic arthritis), Lucentis (or ranibizumab) (e.g., for age-related macular degeneration), Tasigna (or nilotinib) (e.g., for chronic myeloid leukemia), Sandostatin (or octreotide) (e.g., for acromegaly), Gleevec (or imatinib) (e.g., for leukemia, chronic myeloid leukemia (chronic This may include myeloid (CML), Afinitor (or everolimus) (e.g., for tumors), Galvus (or vildagliptin) (e.g., for diabetes), Promacta (or eltrombopag) (e.g., for thrombocytopenic purpura or immunothrombocytopenia (ITP)), and Tafinlar (or dabrafenib) (e.g., for melanoma).

[0137] Non-limiting further examples of non-cannabinoid therapeutic compounds (with applicable therapeutic indications) disclosed herein may include one or more therapeutic agents listed in Table 6. [Table 6-1] [Table 6-2]

[0138] Non-limiting further examples of non-cannabinoid therapeutic compounds (with applicable therapeutic uses) disclosed herein may include one or more cardiovascular therapeutics listed in Table 7. [Table 7]

[0139] Non-limiting further examples of non-cannabinoid therapeutic compounds disclosed herein (having applicable therapeutic indications) may include Entyvio (or vedolizumab) (e.g., for ulcerative colitis, Crohn's disease), Velcade (bortezomib) (e.g., for multiple myeloma), Leuprorelin (or leuprolide) (e.g., for prostate cancer, breast cancer, endometriosis), Azilva (or azilsartan medoxomil) (e.g., for hypertension), Dexilant (or dexlansoprazole) (e.g., for acid reflux), and Ninlaro (or ixazomib) (e.g., for multiple myeloma).

[0140] Non-limiting further examples of non-cannabinoid therapeutic compounds (with applicable therapeutic applications) disclosed herein may include one or more gastrointestinal agents listed in Table 8. [Table 8]

[0141] Non-limiting further examples of non-cannabinoid therapeutic compounds disclosed herein (with applicable therapeutic indications) include Genvoya (or a combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) (e.g., for the treatment of HIV), Truvada (or emtricitabine / tenofovir) (e.g., for the treatment of HIV), Epclusa (or sofosbuvir / velpatasvir) (e.g., for pre-exposure prophylaxis (PrEP)), and Odefsey (or a combination of emtricitabine, rilpivirine, and tenofovir alafenamide) (e.g., for the treatment of hepatitis C). This may include Descovy (or emtricitabine / tenofovir) (for example, for cirrhosis), Atripla (or ledipasvir / sofosbuvir) (for example, for the treatment of HIV), Atripla (or efavirenz / emtricitabine / tenofovir) (for example, for the treatment of HIV), Biktarvy (or bictegravir, emtricitabine, and tenofovir alafenamide) (for example, for the treatment of hepatitis C), Letairis (or ambrisentan) (for example, for the treatment of HIV), and Ranexa (or lanolazine) (for example, for the treatment of HIV).

[0142] Non-limiting further examples of non-cannabinoid therapeutic compounds (with applicable therapeutic applications) disclosed herein may include one or more steroids listed in Table 9. [Table 9]

[0143] Further non-limiting examples of non-cannabinoid therapeutic compounds disclosed herein (with applicable therapeutic indications) include Copaxone (or glatiramer acetate) (e.g., for relapsing-remitting MS), Bendeka (or bendamustine) (e.g., for leukemia, chronic lymphocytic non-Hodgkin lymphoma), methylphenidate hydrochloride (e.g., for attention deficit disorder / hyperactivity (ADD / ADHD)), ProAir HFA (or albuterol) (e.g., for asthma), Austedo (or deutetrabenazine) (e.g., for Huntington's disease, tardive dyskinesia), methylphenidate hydrochloride (e.g., for attention deficit disorder / hyperactivity (ADD / ADHD)), and QVAR. This may include RediHaler (or beclomethasone dipropionate HFA) (e.g., for asthma), Cubicin (or daptomycin) (e.g., for skin infections, endocarditis), metoprolol succinate (e.g., for hypertension), and sildenafil citrate (e.g., for erectile dysfunction).

[0144] Further non-limiting examples of non-cannabinoid therapeutic compounds (with applicable therapeutic uses) disclosed herein may include one or more commercially available (OTC) health products listed in Table 10. [Table 10-1] [Table 10-2]

[0145] Further non-limiting examples of non-cannabinoid therapeutic compounds (having applicable therapeutic applications) disclosed herein may include hypochlorous acid (HOCl) (for example, for blepharitis).

[0146] Non-limiting examples of disease conditions that can be remitted or treated with the non-cannabinoid therapeutic compounds disclosed herein include rheumatoid arthritis, various cancers or tumors (e.g., breast cancer, bone cancer (e.g., osteosarcoma), colorectal cancer, lung cancer, kidney cancer, cervical cancer, ovarian cancer, recurrent glioblastoma, hematological cancer, fallopian tube cancer, kidney cancer, prostate cancer), kidney disease, anemia, arthritis, severe psoriasis vulgaris, secondary hyperparathyroidism, testosterone deficiency, cystic fibrosis, and parkinary tract disease. Son's disease, Crohn's disease, psoriasis vulgaris, chronic lymphocytic leukemia, cholesterol status (e.g., high cholesterol), pain associated with endometriosis, psoriasis vulgaris, viral infections (e.g., syncytial virus (RSV), DIV / AIDS), asthma, chronic obstructive pulmonary disease (COPD), wheezing, shortness of breath, seizures, mood swings, bipolar disorder, benign prostatic hyperplasia (BPH), bacterial infections, rotavirus gastroenteritis, prevention of herpes zoster, diabetes (e.g., type 1 or type 2 diabetes). ), obesity, vasculitis, macular degeneration, myocardial infarction, pulmonary fibrosis, relapsing-remitting MS (RRMS), thrombosis, heart attack, stroke, Pompe disease, eczema, dermatitis, Fabry disease, erectile dysfunction, osteoporosis, psoriasis, anxiety, depression, atrial fibrillation, hemophilia, hypertension, prevention of myocardial infarction, multiple sclerosis, acid reflux, deep vein thrombosis, pulmonary embolism, melanoma, leukemia, hepatitis B, multiple myeloma, psoriasis, deep vein thrombosis, pulmonary embolism, schizophrenia, pneumococcal vaccine, epilepsy, neuropathy, addiction (e.g., drugs, alcohol) This may include conditions such as leukemia (or smoking addiction), menopause, autoimmune diseases, psoriasis, ankylosing spondylitis, psoriatic arthritis, macular degeneration, chronic myeloid leukemia, acromegaly, chronic myeloid leukemia (CML), thrombocytopenic purpura or immune thrombocytopenia (ITP), ulcerative colitis, Crohn's disease, endometriosis, acid reflux, pre-exposure prophylaxis (PrEP), treatment of hepatitis C, cirrhosis, non-Hodgkin lymphoma, attention deficit disorder / hyperactivity disorder (ADD / ADHD), tardive dyskinesia, skin infections, and endocarditis.

[0147] Non-limiting examples of disease conditions that can be remitted or treated with the non-cannabinoid therapeutic compounds disclosed herein include central nervous system (CNS) disorders, such as addiction, arachnoid cysts, attention-deficit / hyperactivity disorder (ADHS), autism, bipolar disorder, catalepsy, depression, encephalitis, epilepsy / seizures, infections, locked-in syndrome, meningitis, migraines, multiple sclerosis, myelopathy, neurodegenerative disorders, such as Alzheimer's disease, Huntington's disease, or Parkinson's disease. In some embodiments, the non-cannabinoid therapeutic compounds disclosed herein can be used as chemotherapeutic agents, anesthetic reversals, contraceptives, antiplatelet agents, post-tissue transplantation drugs (e.g., kidney transplants), or vaccines.

[0148] In some embodiments, compositions of the Disclosure comprising cannabinoids and non-cannabinoid therapeutic compounds may be administered to a subject. The subject may have or be suspected of having a certain condition (e.g., cancer). The subject's condition may be cancer of the breast, lung, stomach, ovary, or other organ or tissue. In some embodiments, the non-cannabinoid therapeutic compound may comprise or be doxorubicin. After administration, the subject may be characterized by at least partial remission of the condition. For example, after administration of a composition of the Disclosure comprising cannabinoids and a non-cannabinoid therapeutic compound comprising doxorubicin, the subject may be characterized by at least partial reduction or remission of the cancer. Compositions comprising cannabinoids and doxorubicin (non-cannabinoid therapeutic compounds) may reduce the negative side effects of doxorubicin in a subject. Combination therapeutic compositions comprising cannabinoids and doxorubicin may reduce cardiomyopathy during the treatment of cancer by activating, binding to, or otherwise interacting with endogenous cannabinoid receptors in the heart. Alternatively or additionally, combination therapeutic compositions may alleviate cardiomyopathy via the mitochondrial pathway during cancer treatment. Administration of compositions containing cannabinoids in addition to non-cannabinoid therapeutic compounds such as doxorubicin may result in improved patient outcomes compared to individual administrations of either cannabinoids or non-cannabinoid therapeutic compounds.

[0149] The structure of doxorubicin is, [ka] It may be a salt, stereoisomer, or prodrug thereof.

[0150] In some embodiments, the combination therapeutic compositions of the Disclosure, comprising cannabinoids and non-cannabinoid therapeutic compounds, may be administered to a subject. The subject may have or be suspected of having a certain condition, the treatment of which may involve the administration of a non-cannabinoid therapeutic compound (e.g., ketamine). In some cases, treatment of the condition by administering the combination therapeutic compositions of the Disclosure may improve the treatment of the condition. In some embodiments, the non-cannabinoid therapeutic compound may include or be ketamine. After administration, the subject may be characterized by at least partial remission of the condition. Alternatively or additionally, after administration of a composition comprising cannabinoids and non-cannabinoid therapeutics, the subject may be characterized by at least partial reduction of negative side effects compared to individual administrations of the non-cannabinoid therapeutic compound. For example, after administration of a composition comprising cannabinoids and ketamine, the subject may be characterized by one or more of reduced motor impairment, antidepressant effects, and assistance in fear elimination in neural networks.

[0151] The structure of ketamine is, [ka] It may be a salt, stereoisomer, or prodrug thereof.

[0152] In some embodiments, the combination therapeutic compositions of this disclosure, comprising cannabinoids and non-cannabinoid therapeutic compounds, may be administered to a subject. The subject may have or be suspected of having a certain condition (e.g., high cholesterol). In some cases, the condition may be one that is treated by the administration of statins. In some embodiments, the non-cannabinoid therapeutic compound may or may be a statin (e.g., atorvastatin, fluvastatin, pravastatin, rosuvastatin, simvastatin). After administration of a composition comprising cannabinoids and non-cannabinoid therapeutic compounds (e.g., statins), the subject may be characterized by at least partial remission of the condition. After administration, the subject may be characterized by improved (e.g., reduced) cholesterol levels and / or neuroprotective effects from the administration of the combination therapeutic composition.

[0153] The structure of atorvastatin is, [ka] It may be a salt, stereoisomer, or prodrug thereof.

[0154] The structure of fluvastatin is, [ka] It may be a salt, stereoisomer, or prodrug thereof.

[0155] The structure of lovastatin is [ka] It may be a salt, stereoisomer, or prodrug thereof.

[0156] In some embodiments, the combination therapeutic compositions of this disclosure, comprising cannabinoids and non-cannabinoid therapeutic compounds, may be administered to a subject. The subject may have or be suspected of having a certain condition, the treatment of which may involve the administration of a non-cannabinoid therapeutic compound. In some cases, the treatment of the condition may be improved by the administration of a combination therapeutic composition comprising cannabinoids and non-cannabinoid therapeutics. In some embodiments, the non-cannabinoid therapeutic compound may or may be dextromethorphan. After administration, the subject may be characterized by at least partial remission of the condition. For example, the subject may have a condition (e.g., cough) that can be alleviated by the administration of dextromethorphan. After administration of a combination therapeutic composition comprising cannabinoids and dextromethorphan, the subject may be characterized by reduced inflammation and enhanced hepatoprotection. Administration of a combination therapeutic composition comprising cannabinoids and dextromethorphan may improve the treatment or reduce one or more negative effects of non-cannabinoid therapeutics. In some cases, administration of a combination therapeutic composition may improve the treatment of the target cough by reducing inflammation. In other cases, administration of a combination therapeutic composition containing cannabinoids and dextromethorphan may result in enhanced hepatoprotection compared to individual administrations of dextromethorphan.

[0157] The structure of dextromethorphan is, [ka] It may be a salt, stereoisomer, or prodrug thereof.

[0158] In some embodiments, the combination therapeutic compositions of this disclosure, comprising cannabinoids and non-cannabinoid therapeutic compounds, may be administered to a subject. The subject may have or be suspected of having a certain condition, the treatment of which may involve the administration of a non-cannabinoid therapeutic compound. In some cases, the treatment of the condition may be improved by the administration of a combination therapeutic composition comprising cannabinoids and non-cannabinoid therapeutics. In some embodiments, the non-cannabinoid therapeutic compound may or may be an NSAID (e.g., ibuprofen, acetaminophen, or naproxen). After administration, the subject may be characterized by at least partial remission of the condition. For example, the subject may have a condition (e.g., pain, inflammation, fever, headache, or arthritis) that can be alleviated by the administration of an NSAID. After administration of a combination therapeutic composition comprising cannabinoids and NSAIDs, the subject may be characterized by reduced inflammation and enhanced hepatoprotection. Administration of a combination therapeutic composition comprising cannabinoids and NSAIDs may improve the treatment or reduce the negative effects of one or more non-cannabinoid therapeutics. In some cases, administration of a combination therapeutic composition may improve the treatment of the condition by reducing inflammation. In other cases, administration of a combination therapeutic composition containing cannabinoids and NSAIDs may result in enhanced hepatoprotection compared to individual administrations of NSAIDs.

[0159] The structure of ibuprofen is, [ka] It may be a salt, stereoisomer, or prodrug thereof.

[0160] The structure of acetaminophen is, [ka] It may be a salt, isomer, or prodrug thereof.

[0161] The structure of naproxen is, [ka] It may be a salt, stereoisomer, or prodrug thereof.

[0162] In some embodiments, the combination therapeutic compositions of this disclosure, comprising cannabinoid and non-cannabinoid therapeutic compounds, may be administered to a subject. The subject may have or be suspected of having a certain condition, the treatment of which may involve the administration of a non-cannabinoid therapeutic compound. In some embodiments, the non-cannabinoid therapeutic compound may include, or may be, benzodiazepines (e.g., alprazolam, estazolam, flunitrazepam, clonazepam, lormetazepam, midazolam, lorazepam, nitrazepam, and temazepam, chlordiazepoxide, clorazepate, diazepam, lorazepam, harazepam, oxazepam, prazepam, or quazepam). Following administration, the subject may be characterized by at least partial remission of the condition. For example, a subject may have a condition that can be alleviated by the administration of benzodiazepines (e.g., anxiety, panic attacks, depression, insomnia, seizures, or nausea (naseua)). After administration of a combination therapeutic composition containing cannabinoids and benzodiazepines, the subject may be characterized by one or more of the following compared to individual administrations of benzodiazepines: improved anxiolytic effect, lower addictive potential, and protection of the subject's liver and brain.

[0163] The structure of diazepam is, [ka] It may be a salt, isomer, or prodrug thereof.

[0164] The structure of alprazolam is [ka] It may be a salt, isomer, or prodrug thereof.

[0165] The structure of clonazepam is, [ka] It may be a salt, isomer, or prodrug thereof.

[0166] The structure of temazepam is, [ka] It may be a salt, isomer, or prodrug thereof.

[0167] Without being bound by any particular theory, the combination therapies disclosed herein, consisting of (i) one or more cannabinoid compounds and (ii) one or more non-cannabinoid therapeutic compounds, may promote or induce unique therapeutic effects (e.g., synergistic effects in a subject, or different effects not induced by either (i) or (ii) alone). For example, combination therapy may enhance the efficacy (e.g., therapeutic efficacy) of (i) and / or (ii) by at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, or more, compared to therapy using either (i) or (ii) alone. In another example, combination therapy may induce therapeutic pathways (e.g., cellular signaling pathways) that are not activated by therapy using either (i) or (ii) alone.

[0168] Without being bound by any particular theory, the combination therapies disclosed herein, consisting of (i) one or more cannabinoid compounds and (ii) one or more non-cannabinoid therapeutic compounds, may enhance the efficacy of either (i) or (ii) alone in a subject (i.e., enhance the overall outcome).

[0169] Without being bound by any theory, the combination therapies disclosed herein, comprising (i) one or more cannabinoid compounds and (ii) one or more non-cannabinoid therapeutic compounds, can enhance the therapeutic range of either (i) or (ii) alone or both in a subject (e.g., a drug dose that can effectively treat the disease without toxic effects). For example, combination therapy can increase the therapeutic range of one or more non-cannabinoid therapeutic compounds in a subject by at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, or more, compared to therapy using one or more non-cannabinoid therapeutic compounds in the absence of one or more cannabinoid compounds.

[0170] Without being bound by any theory, the combination therapies disclosed herein, comprising (i) one or more cannabinoid compounds and (ii) one or more non-cannabinoid therapeutic compounds, can delay, reduce, or prevent the side effects of either (i) or (ii) alone in a subject (e.g., off-target effects, toxicity, addiction, etc.). For example, combination therapy can reduce the side effects of one or more non-cannabinoid therapeutic compounds in a subject by at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%, or more, compared to therapy using one or more non-cannabinoid therapeutic compounds in the absence of one or more cannabinoid compounds.

[0171] In another embodiment, the Disclosure provides a composition comprising a plurality of microcapsules, wherein each of the plurality of microcapsules comprises one or more therapeutic compositions, and the microcapsules are neither liposomes nor micelles.

[0172] In another embodiment, the Disclosure provides a composition comprising a plurality of microcapsules, wherein each microcapsule contains one or more therapeutic compositions, and the compositions have a storage half-life of at least 30 days. In yet another embodiment, the Disclosure provides a food rich in therapeutic compositions. Microfluidic encapsulation and delivery

[0173] The compositions disclosed herein may include microcapsules. Microcapsules may contain, in microencapsulated form, components discussed elsewhere in this disclosure, such as mushroom, fulvic acid, L-theanine, fish oil, pregnenolone, phenylethylamine (PEA), tulsi, lemon balm, passionflower, terpene compounds, blue lotus, cocoa, maca, schizandra, ginseng, kava, scutellaria, valerian, hops, California poppy, catuaba, epimedium, pau d'arco, ashwaganda, ginkgo, albiza, reishi mushroom, lion's mane, maitake, chaga, vitamin C, turmeric, cannabinoid compounds, cannabidiol (CBD), tetrahydrocannabinol (THC), bioperine, and xanthohumol oil-based compounds. In some cases, the composition can be encapsulated without the use of liposomes. In some cases, the composition can be encapsulated without the use of micelles. In some cases, the composition can be encapsulated without the use of either liposomes or micelles. The compounds of the composition can exist within microcapsules in forms including, but not limited to, liquids, gels, semi-solids, and solids. Microcapsules of compositions disclosed herein can be further processed into forms including, but not limited to, solids, powders, liquids, suspensions, gels, tablets, foods, lotions, cosmetics, and other forms discussed herein.

[0174] Microencapsulation can be performed using microencapsulation devices, including microfluidic droplet generators or encapsulation devices. An exemplary microencapsulation device is described, for example, in U.S. Patent No. 7,482,152, which is incorporated herein by reference in its entirety. Microfluidic droplets or emulsions can be generated by a flow of fluid to be encapsulated using an immiscible carrier fluid. For example, an oil fluid to be encapsulated can be flowed together with an aqueous carrier fluid, or an aqueous fluid to be encapsulated can be flowed together with an oil carrier fluid. Air can also be used as the fluid. Microfluidic droplet generators useful for microencapsulation include those using parallel flow, cross flow (e.g., flow at a T-junction), flow focusing, flow through a perforated plate, and flow through a nozzle. Droplet size can be controlled by parameters including the device geometry, relative fluid flow velocity, and operating pressure.

[0175] Figure 1A shows an example of a droplet generator. In the three-dimensional structure 1800, a first phase (e.g., oil) is transferred from a first fluid chamber 1802 through two branches of a fluid channel section 1804. The first phase exiting the first fluid chamber 1802 intersects with a second phase (e.g., a water phase) which exits the second fluid chamber 1806 and travels along a fluid channel section 1808 to an intersection 1810 with the fluid channel section 1804. For example, the first phase exiting the first fluid chamber 1802 arrives at the intersection 1810 from two different substantially opposite directions, while the second phase arrives at the intersection along only a single path, which is substantially perpendicular to both directions of movement of the incoming first phase fluid. At intersection 1810, droplets in the second phase are generated in the background of the first phase (e.g., water-in-oil emulsion) and transferred along the fluid channel section 1812 to the third fluid chamber 1814, where the emulsion is temporarily stored and / or transferred to another location. These phases can be reversed, for example, so that droplets in the first phase are generated in the background of the second phase (e.g., oil-in-water emulsion).

[0176] Figure 1B shows another example of a droplet generator. In the three-dimensional structure 1815, the first phase (e.g., oil) is transferred from the first fluid chamber 1816 through two branches of the fluid channel section 1818. The fluid channel section 1818 intersects at intersection 1824 with the fluid channel section 1822, which transfers the fluid of the second phase (e.g., aqueous solution) exiting the second fluid chamber 1820. As seen in the three-dimensional structure 1800 in Figure 1A, the first phase exiting the first fluid chamber 1816 reaches intersection 1810 from two different directions, but unlike the three-dimensional structure 1800, the fluid does not arrive from substantially opposite (antiparallel) directions. Rather, the branches of the channel section 1818 each intersect with the channel section 1822 at non-perpendicular angles, which are illustrated as approximately 60 degrees in Figure 1B. Generally, the stereostructure 1815 may include fluid channels of the first phase that intersect the fluid channels of the second phase at one or more arbitrary desired angles. The fluid of the first phase flowing through channel section 1818 and the fluid of the second phase flowing through channel section 1822 can be combined to form an emulsion of droplets in the second phase suspended in the background of the first phase (e.g., a water-in-oil emulsion). The droplets can then be transferred to a third fluid chamber 1828 along the fluid channel section 1826 for storage and / or transfer to another location, as seen in the case of stereostructure 1800. These phases can be reversed, for example, so that droplets in the first phase are generated in the background of the second phase (e.g., an oil-in-water emulsion).

[0177] Figure 1C shows an example of a microfluidic structure. The arrows in the illustrated fluid channels indicate the direction of fluid flow within each channel. Fluid chambers for receiving and / or storing oil, water, and any resulting emulsions are not shown, but these chambers or sources of at least some oil and aqueous fluids may be located within a cartridge containing one of the illustrated three-dimensional structures. Fluid channels and any associated chambers may be formed by any suitable method, as already described, e.g., by sections complementary to injection molding of thermoplastic materials. In the three-dimensional structure 1850 of the T-junction, the fluid of the first phase moving along channel 1852 intersects with the fluid of the second phase moving along channel 1854 to intersection 1856, generating an emulsion of the second phase in the first phase (e.g., water in oil, oil in water, etc.), which moves outward along fluid channel 1858. The droplets formed in the three-dimensional structure 1850 of the T-junction may be formed primarily by shear mechanisms rather than primarily by compression mechanisms. However, droplet formation can vary depending on many factors, including channel diameter, fluid velocity, and fluid viscosity.

[0178] Microencapsulation can be performed at a given range of operating parameters, such as different flow rates or pressures. Microencapsulation can be performed at pressures of at least approximately 10 pounds / square inch (psi), 20 psi, 30 psi, 40 psi, 50 psi, 60 psi, 70 psi, 80 psi, 90 psi, 100 psi, 200 psi, 300 psi, 400 psi, 500 psi, 600 psi, 700 psi, 800 psi, 900 psi, 1000 psi, 2000 psi, 3000 psi, 4000 psi, 5000 psi, 6000 psi, 7000 psi, 8000 psi, 9000 psi, 10000 psi, 15000 psi, 20000 psi, 25000 psi, 30000 psi, 35000 psi, 40000 psi, 45000 psi, 50000 psi, or above. Microencapsulation can be performed at pressures of up to approximately 10 pounds / square inch (psi), 20 psi, 30 psi, 40 psi, 50 psi, 60 psi, 70 psi, 80 psi, 90 psi, 100 psi, 200 psi, 300 psi, 400 psi, 500 psi, 600 psi, 700 psi, 800 psi, 900 psi, 1000 psi, 2000 psi, 3000 psi, 4000 psi, 5000 psi, 6000 psi, 7000 psi, 8000 psi, 9000 psi, 10000 psi, 15000 psi, 20000 psi, 25000 psi, 30000 psi, 35000 psi, 40000 psi, 45000 psi, or 50000 psi. Microencapsulation can be performed at pressures of approximately 10 pounds / square inch (psi), 20 psi, 30 psi, 40 psi, 50 psi, 60 psi, 70 psi, 80 psi, 90 psi, 100 psi, 200 psi, 300 psi, 400 psi, 500 psi, 600 psi, 700 psi, 800 psi, 900 psi, 1000 psi, 2000 psi, 30000 psi, 4000 psi, 5000 psi, 6000 psi, 7000 psi, 8000 psi, 9000 psi, 10000 psi, 15000 psi, 20000 psi, 25000 psi, 30000 psi, 35000 psi, 40000 psi, 45000 psi, 50000 psi, or higher.Microencapsulation is possible at a minimum of approximately 1 mL / min, 2 mL / min, 3 mL / min, 4 mL / min, 5 mL / min, 6 mL / min, 7 mL / min, 8 mL / min, 9 mL / min, 10 mL / min, 20 mL / min, 30 mL / min, 40 mL / min, 50 mL / min, 60 mL / min, 70 mL / min, 80 mL / min, 90 mL / min, 100 mL / min, 110 mL / min, 120 mL / min, 130 mL / min, 140 mL / min, 150 mL / min, 160 mL / min, 170 mL / min, 180 mL / min, 190 mL / min, 200 mL / min, 210 mL / min, 220 mL / min, 230 mL / min, 240 mL / min, 25 Flow rates of 0 mL / min, 260 mL / min, 270 mL / min, 280 mL / min, 290 mL / min, 300 mL / min, 310 mL / min, 320 mL / min, 330 mL / min, 340 mL / min, 350 mL / min, 360 mL / min, 370 mL / min, 380 mL / min, 390 mL / min, 400 mL / min, 410 mL / min, 420 mL / min, 430 mL / min, 440 mL / min, 450 mL / min, 460 mL / min, 470 mL / min, 480 mL / min, 490 mL / min, 500 mL / min, or higher are possible. Microencapsulation can be performed at a maximum of approximately 1 ml / min (mL / min), 2 mL / min. 3mL / min, 4mL / min, 5mL / min, 6mL / min, 7mL / min, 8mL / min, 9mL / min, 10mL / min, 20mL / min, 30mL / min, 40mL / min, 50mL / min, 60mL / min, 70mL / min, 80mL / min, 90mL / min, 100mL / min , 110mL / min, 120mL / min, 130mL / min, 140mL / min, 150mL / min, 160mL / min, 170mL / min, 180mL / min, 190mL / min, 200mL / min, 210mL / min, 220mL / min, 230mL / min, 240mL / min This can be done at flow rates of 250 mL / min, 260 mL / min, 270 mL / min, 280 mL / min, 290 mL / min, 300 mL / min, 310 mL / min, 320 mL / min, 330 mL / min, 340 mL / min, 350 mL / min, 360 mL / min, 370 mL / min, 380 mL / min, 390 mL / min, 400 mL / min, 410 mL / min, 420 mL / min, 430 mL / min, 440 mL / min, 450 mL / min, 460 mL / min, 470 mL / min, 480 mL / min, 490 mL / min, or 500 mL / min.Microencapsulation allows for infusion rates of approximately 1 mL / min, 2 mL / min, 3 mL / min, 4 mL / min, 5 mL / min, 6 mL / min, 7 mL / min, 8 mL / min, 9 mL / min, 10 mL / min, 20 mL / min, 30 mL / min, 40 mL / min, 50 mL / min, 60 mL / min, 70 mL / min, 80 mL / min, 90 mL / min, 100 mL / min, 110 mL / min, 120 mL / min, 130 mL / min, 140 mL / min, 150 mL / min, 160 mL / min, 170 mL / min, 180 mL / min, 190 mL / min, 200 mL / min, 210 mL / min, 220 mL / min, 230 mL / min, 240 mL / min, and 25 mL / min. It can be performed at flow rates of 0 mL / min, 260 mL / min, 270 mL / min, 280 mL / min, 290 mL / min, 300 mL / min, 310 mL / min, 320 mL / min, 330 mL / min, 340 mL / min, 350 mL / min, 360 mL / min, 370 mL / min, 380 mL / min, 390 mL / min, 400 mL / min, 410 mL / min, 420 mL / min, 430 mL / min, 440 mL / min, 450 mL / min, 460 mL / min, 470 mL / min, 480 mL / min, 490 mL / min, 500 mL / min, or higher.

[0179] A droplet generator can use multiple parallel droplet production operations in parallel. For example, a droplet generator (e.g., a device with plates and channels) can use at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more droplet generation features (e.g., holes, channels, nozzles). A droplet generator can use up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 droplet generation features. The droplet generator can use approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more droplet generation features.

[0180] Microencapsulation can be carried out through an emulsification process. For example, a composition can be emulsified in a mixer such as a stirrer, impeller, centrifugal mixer, or high-shear mixer. High-shear mixers can include batch high-shear mixers and in-line high-shear mixers (e.g., rotor-stator mixers). Emulsification can also be performed without a mixer by combining a thermodynamically preferred fluid to form an emulsion with the help of one or more emulsifiers or surfactants as needed.

[0181] The microencapsulation process can be carried out with the help of one or more emulsifiers or surfactants. Emulsifiers and surfactants may include, but are not limited to, saponins (e.g., Quillaja tree extract such as Q-NATURALE®, yucca extract), lecithin, soy lecithin, mustard seed husk extract, sodium stearoyl lactylate, polysorbate 20, and combinations thereof.

[0182] Microcapsules may contain one or more stabilizers or gelling agents that can be used to stabilize the microcapsules or emulsions. These stabilizers or gelling agents may include, but are not limited to, alginates (also known as algin or alginic acid) and agar. Alginates may be used in a variety of forms, including, but are not limited to, inorganic salts such as sodium alginate, potassium alginate, calcium alginate, and combinations thereof. Alginates may be derived from sources such as seaweed (e.g., Macrocystis pyrifera, Ascophyllum nodosum, Laminaria spp.) or bacteria (e.g., Pseudomonas spp., Azotobacter spp.). Crosslinking agents or solutions, such as calcium chloride, may be used to stabilize or gel the microcapsules.

[0183] Microcapsules can be characterized by their size (e.g., diameter). The size of a microcapsule may be approximately 0.154 micrometers. The size of a microcapsule may be less than or equal to approximately 0.154 micrometers. The size of a microcapsule may be greater than or equal to approximately 0.154 micrometers. The sizes of microcapsules may be approximately 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, It may be 0.8, 0.85, 0.9, 0.95, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, or 500 micrometers. The microcapsule sizes are approximately 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.8 It can be less than or equal to 5, 0.9, 0.95, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, or 500 micrometers.The microcapsule sizes are approximately 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, The size of the microcapsules can be greater than or equal to 0.9, 0.95, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, or 500 micrometers. The size of the microcapsules can be about 0.1 to about 0.2 micrometers. The size of the microcapsules can be about 0.05 to about 0.25 micrometers. The size of the microcapsules can be about 0.05 to about 0.55 micrometers. The size of the microcapsules can be about 0.05 to about 1 micrometer. The size distribution in a population of microcapsules may be homogeneous or substantially homogeneous. For example, a population of microcapsules may have sizes approximately 20, 19, 18, 17, 16, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4.9, 4.8, 4.7, 4.6, 4.5, 4.4, 4.3, 4.2, 4.1, 4.0, 3.9, 3.8, 3.7, 3.6, 3.5, 3.4, 3.3, 3.2, 3.1, 3.0, 2.9, 2.8, 2.7, 2.6, 2.5, 2.4, 2.3, 2.2, 2.1. It can be characterized by a variance or multivariance index (PDI) of 2.0, 1.9, 1.8, 1.7, 1.6, 1.5, 1.45, 1.40, 1.35, 1.30, 1.25, 1.20, 1.15, 1.14, 1.13, 1.12, 1.11, 1.10, 1.09, 1.08, 1.07, 1.06, 1.05, 1.04, 1.03, 1.02, 1.01, or less than or equal to 1.00. Solid composition and delivery

[0184] The compositions of this disclosure may include solid compositions (e.g., tablets, pills, etc.).

[0185] Figures 5A–5D show various examples of solid compositions (e.g., tablets) disclosed herein. As shown in Figure 5A, a tablet may include a mixture (e.g., a homogeneous or heterogeneous mixture) of a non-cannabinoid therapeutic compound 501 and a cannabinoid compound 503. As shown in Figure 5B, a tablet may include a first layer containing the non-cannabinoid therapeutic compound 501 and a second layer containing the cannabinoid compound 503. As shown in Figure 5C, a tablet may include an intermediate layer containing the non-cannabinoid therapeutic compound 501, positioned between at least two layers containing the cannabinoid compound 503. As shown in Figure 5D, a tablet may include a first layer containing the non-cannabinoid therapeutic compound 501, a third layer containing the cannabinoid compound 503, and a second layer containing a filler or a different therapeutic compound 505, positioned between the first and second layers.

[0186] Figures 6A–6D show various examples of solid compositions (e.g., pills) disclosed herein. As shown in Figure 6A, a pill may include a mixture (e.g., a homogeneous or heterogeneous mixture) of a non-cannabinoid therapeutic compound 601 and a cannabinoid compound 603. As shown in Figure 6B, a pill may include a first layer containing the non-cannabinoid therapeutic compound 601 and a second layer containing the cannabinoid compound 603. As shown in Figure 6C, a pill may include an intermediate layer containing the non-cannabinoid therapeutic compound 601, positioned between at least two layers containing the cannabinoid compound 603. As shown in Figure 6D, a pill may include a first layer containing the non-cannabinoid therapeutic compound 601, a third layer containing the cannabinoid compound 603, and a second layer containing a filler or a different therapeutic compound 605, positioned between the first and second layers. composition

[0187] The therapeutic compositions of the present disclosure may include a variety of compounds such as mushroom, fulvic acid, L-theanine, fish oil, pregnenolone, phenylethylamine (PEA), tulsi, lemon balm, passionflower, terpene compounds, blue lotus, cocoa, maca, schisandra, ginseng, kaba, scutellaria, valerian, hops, California poppy, catuaba, epimedium, pau d'arco, ashwagandha, ginkgo, albiza, reishi mushroom, lion's mane, maitake, chaga, vitamin C, turmeric, cannabinoid compounds, cannabidiol (CBD), tetrahydrocannabinol (THC), bioperine, xanthohumol oil-based compounds, and / or combinations thereof.The cannabinoids used in the compositions disclosed herein include cannabigerol type (CBG), cannabigerol acid (CBGA), cannabigerol acid monomethyl ether (CBGAM), cannabigerol monomethyl ether (CBGM), cannabichromene type (CBC), cannabichromanone (CBCN), cannabichromene acid (CBCA), cannabiclomevalin type (CBCV), cannabiclomevalic acid (CBCVA), cannabidiol type (CBD), tetrahydrocannabinol type (THC), isotetrahydrocannabinol type (iso-THC), cannabinol type (CBN), cannabinol acid (CBNA), cannabinol methyl ether (CBNM), cannabinol-C4 (CBN-C4), cannabinol-C2 (CBN-C2), cannabiolcol (CBN-C1), and This includes, but is not limited to, cannabinodiol (CBND), cannabiersoin type (CBE), cannabiersonate A (CBEA-A), cannabiersonate B (CBEA-B), cannabicyclool type (CBL), cannabicycloalic acid (CBLA), cannabicyclovaline (CBLV), cannabicitran type (CBT), cannabitriol, cannabitriol valine (CBTV), ethoxycannabithiol valine (CBTVE), cannabivarin type (CBV), cannabinodivaline (CBVD), tetrahydrocannabivarin type (THCV), cannabidivaline type (CBDV), cannabigerovaline type (CBGV), cannabigerovalic acid (CBGVA), cannabifuran (CBF), dehydrocannabifuran (DCBF), and cannabilipsol (CBR) cannabinoids.

[0188] The cannabinoids used in the compositions of this disclosure may be derived from a variety of sources, including, but are not limited to, hemp (e.g., hemp stalks, hemp stems, hemp seeds), cannabis (e.g., cannabis flowers, cannabis leaves, cannabis stalks, cannabis stems, cannabis seeds), Echinacea purpurea, Echinacea angustifolia, Echinacea pallida, Acmella oleracea, Helichrysum umbraculigerum, Radula marginata, kava, black truffle, Syzygium aromaticum (clove), Rosmarinus oficinalis, basil, oregano, black pepper, lavender, true cinnamon, marabatrum, cananga odorata, copaifera spp., and hops.

[0189] Encapsulated cannabinoids can be present in amounts of at least approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 nanograms, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule. Encapsulated cannabinoids can be present in amounts of up to approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 nanograms, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule. Encapsulated cannabinoids can be present in amounts of approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 nanograms, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule. Encapsulated cannabinoids can be present in amounts of approximately 1 to approximately 10 micrograms per microcapsule.The encapsulated cannabinoids may be present in amounts of at least about 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight of the microcapsule. Encapsulated cannabinoids can be present in microcapsules in amounts of approximately 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight. Encapsulated cannabinoids can be present in amounts of approximately 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight of the microcapsule.

[0190] Cannabinoids may be present in a composition (e.g., product, e.g., drug unit dose or food) in amounts of at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg). Cannabinoids may be present in a composition (e.g., a product, e.g., a drug unit dose or food) in amounts of up to approximately 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg). Cannabinoids can be present in a composition (e.g., product, e.g., drug unit dose or food) in amounts of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg). Cannabinoids can be present in a composition (e.g., product, e.g., drug unit dose or food) in amounts of about 50 to about 150 milligrams.Cannabinoids are present in a composition (e.g., product, e.g., drug unit dose or food) at a concentration of at least about 0.01% by weight, 0.02% by weight, 0.03% by weight, 0.04% by weight, 0.05% by weight, 0.06% by weight, 0.07% by weight, 0.08% by weight, 0.09% by weight, 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, and 0.8% by weight of the product. It can exist in amounts of 1%, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight. Cannabinoids are present in a composition (e.g., product, e.g., drug unit dose or food) at a maximum concentration of approximately 0.01% by weight, 0.02% by weight, 0.03% by weight, 0.04% by weight, 0.05% by weight, 0.06% by weight, 0.07% by weight, 0.08% by weight, 0.09% by weight, 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, and 0.8% by weight. It can exist in amounts of %, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight.Cannabinoids are present in compositions (e.g., products, drug unit doses, or food) at concentrations of approximately 0.01% by weight, 0.02% by weight, 0.03% by weight, 0.04% by weight, 0.05% by weight, 0.06% by weight, 0.07% by weight, 0.08% by weight, 0.09% by weight, 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, and 0.8% by weight of the product. It can be present in amounts of 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight.

[0191] The cannabinoids of the compositions disclosed herein may include, but are not limited to, compounds of the class of cannabidiol, including cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidiol monomethyl ether (CBDM), cannabidiol-C4 (CBD-C4), cannabidivaline (CBDV), cannabidivaric acid (CBDVA), cannabidiolcol (CBD-C1), and combinations thereof. CBD may include delta-1-cannabidiol, delta-2-cannabidiol, delta-3-cannabidiol, delta-3,7-cannabidiol, delta-4-cannabidiol, delta-5-cannabidiol, delta-6-cannabidiol, and combinations thereof.

[0192] The encapsulated cannabidiol compound may be present in an amount of at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule. The encapsulated cannabidiol compound can be present in amounts of up to approximately 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule. Encapsulated cannabidiol compounds can be present in amounts of approximately 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule. Encapsulated cannabidiol compounds can be present in amounts of approximately 1 to approximately 10 micrograms per microcapsule. The encapsulated cannabidiol compound may be present in the microcapsules in amounts of at least about 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight.The encapsulated cannabidiol compound can be present in microcapsules in amounts of approximately 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight. The encapsulated cannabidiol compound can be present in amounts of approximately 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight of the microcapsule.

[0193] Cannabidiol compounds may be present in a composition (e.g., a product, e.g., a drug unit dose or food) in amounts of at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg). Cannabidiol compounds can be present in a composition (e.g., a product, e.g., a drug unit dose or food) in amounts of up to about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg). Cannabidiol compounds can be present in a composition (e.g., product, e.g., drug unit dose or food) in amounts of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg). Cannabidiol compounds can be present in a composition (e.g., product, e.g., drug unit dose or food) in amounts of about 50 to about 150 milligrams.Cannabidiol compounds are present in compositions (e.g., products, e.g., drug unit doses or foods) at concentrations of at least about 0.01% by weight, 0.02% by weight, 0.03% by weight, 0.04% by weight, 0.05% by weight, 0.06% by weight, 0.07% by weight, 0.08% by weight, 0.09% by weight, 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, and 0. It can exist in amounts of 8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight. Cannabidiol compounds are present in compositions (e.g., products, e.g., drug unit doses or foods) at a maximum concentration of about 0.01% by weight, 0.02% by weight, 0.03% by weight, 0.04% by weight, 0.05% by weight, 0.06% by weight, 0.07% by weight, 0.08% by weight, 0.09% by weight, 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, and 0.8% by weight. It can exist in amounts of weight %, 0.9 weight%, 1 weight%, 2 weight%, 3 weight%, 4 weight%, 5 weight%, 6 weight%, 7 weight%, 8 weight%, 9 weight%, 10 weight%, 11 weight%, 12 weight%, 13 weight%, 14 weight%, 15 weight%, 16 weight%, 17 weight%, 18 weight%, 19 weight%, 20 weight%, 25 weight%, 30 weight%, 35 weight%, 40 weight%, 45 weight%, or 50 weight%.Cannabidiol compounds are present in compositions (e.g., products, e.g., drug unit doses or foods) at concentrations of approximately 0.01% by weight, 0.02% by weight, 0.03% by weight, 0.04% by weight, 0.05% by weight, 0.06% by weight, 0.07% by weight, 0.08% by weight, 0.09% by weight, 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, and 0.8% by weight of the product. It can exist in amounts of 1%, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight.

[0194] The compositions of this disclosure may include tetrahydrocannabinol (THC) as a certain type of cannabinoid. THC may include delta-9-THC, delta-8-THC, and combinations thereof. THC may include delta-6a,7-tetrahydrocannabinol, delta-7-tetrahydrocannabinol, delta-8-tetrahydrocannabinol, delta-9,11-tetrahydrocannabinol, delta-9-tetrahydrocannabinol, delta-10-tetrahydrocannabinol, delta-6a,10a-tetrahydrocannabinol, and combinations thereof. Delta-9-tetrahydrocannabinol may include stereoisomers, including (6aR,10aR)-delta-9-tetrahydrocannabinol, (6aS,10aR)-delta-9-tetrahydrocannabinol, (6aS,10aS)-delta-9-tetrahydrocannabinol, (6aR,10aS)-delta-9-tetrahydrocannabinol, and combinations thereof.

[0195] If the composition contains microcapsules, the THC compound may be present in amounts of at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule. Encapsulated THC compounds can be present in amounts of up to approximately 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule. Encapsulated THC compounds can be present in amounts of approximately 1 to approximately 10 micrograms per microcapsule. The encapsulated THC compound can be present in amounts of approximately 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule. The encapsulated THC compound may be present in the microcapsule in amounts of at least about 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight.The encapsulated THC compound can be present in microcapsules in amounts of approximately 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight. The encapsulated THC compound may be present in amounts of approximately 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight of the microcapsule.

[0196] THC compounds may be present in a composition (e.g., a product, e.g., a drug unit dose or food) in amounts of at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg). THC compounds can be present in a composition (e.g., a product, e.g., a drug unit dose or food) in amounts of up to about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg). THC compounds can be present in a composition (e.g., product, e.g., drug unit dose or food) in amounts of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg). THC compounds can be present in a composition (e.g., product, e.g., drug unit dose or food) in amounts of about 50 to about 150 milligrams.THC compounds are present in compositions (e.g., products, e.g., drug unit doses or food) at concentrations of at least about 0.01% by weight, 0.02% by weight, 0.03% by weight, 0.04% by weight, 0.05% by weight, 0.06% by weight, 0.07% by weight, 0.08% by weight, 0.09% by weight, 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, and 0.8% by weight of the product. It can exist in amounts of 1%, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight. THC compounds are present in compositions (e.g., products, e.g., drug unit doses or food) at a maximum concentration of about 0.01% by weight, 0.02% by weight, 0.03% by weight, 0.04% by weight, 0.05% by weight, 0.06% by weight, 0.07% by weight, 0.08% by weight, 0.09% by weight, 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, and 0.8% by weight. It can exist in amounts of %, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight.THC compounds are present in compositions (e.g., products, e.g., drug unit doses or food) in amounts of about 0.01% by weight, 0.02% by weight, 0.03% by weight, 0.04% by weight, 0.05% by weight, 0.06% by weight, 0.07% by weight, 0.08% by weight, 0.09% by weight, 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, and 0.8% by weight of the product. It can exist in amounts of 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight.

[0197] In some cases, the compositions of the Disclosure do not contain psychoactive amounts of THC. For example, the cannabinoids in the compositions of the Disclosure may contain THC at a concentration of 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, 1%, 0.7%, 0.5%, 0.3%, or less than 0.1% of the total amount of cannabinoid compounds. In some cases, the ratio of non-THC cannabinoids (e.g., cannabidiol) to THC in the compositions of the Disclosure is about 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, or greater than or equal to 100:1. In some cases, the compositions of the Disclosure contain less than 0.3% THC.

[0198] The compositions of this disclosure may include, but are not limited to, one or more terpene compounds, including terpenoids such as monoterpenoids, sesquiterpenoids, diterpenoids, and triterpenoids. Terpenes may be acyclic, monocyclic, or polycyclic. Examples of terpenes include myrcene, limonene, linalool, trans-ocimene, cis-ocimene, alpha-pinene, beta-pinene, alpha-humulene (alpha-caryophyllene), beta-caryophyllene, delta-3-carene, trans-gamma-bisabolene, cis-gamma-bisabolene, trans-alpha-farnesene, cis-beta-farnesene, beta-fencol, beta-phellandrene, guayole, alpha-guaene, alpha-eoidesmol, beta-eoidesmol, gamma-eoidesmol, This may include, but is not limited to, terpinolene, alpha-selinene, beta-selinene, alpha-terpineol, fencone, camphene, cis-sabinene hydrate, alpha-trans-bergamotene, alpha-cis-bergamotene, borneol, gamma-curcumene, alpha-thugen, epi-alpha-bisabolol, ipsdienol, alpha-ylangene, beta-elemene, gamma-mulorene, alpha-cadinene, alpha-longipinene, caryophyllene oxide, and combinations thereof.

[0199] Encapsulated terpenes can be present in amounts of at least approximately 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule. Encapsulated terpenes can be present in amounts of up to approximately 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule. Encapsulated terpenes can be present in amounts of approximately 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule. Encapsulated terpene compounds can be present in amounts of approximately 1 to approximately 10 micrograms per microcapsule. The encapsulated terpenes may be present in amounts of at least about 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight of the microcapsules.Encapsulated terpenes can be present in amounts of up to approximately 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight in microcapsules. Encapsulated terpenes can be present in amounts of approximately 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight of the microcapsules.

[0200] Terpene compounds may be present in a composition (e.g., a product, e.g., a drug unit dose or food) in amounts of at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg). Terpene compounds may be present in a composition (e.g., a product, e.g., a drug unit dose or food) in amounts of up to about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg). Terpene compounds can be present in a composition (e.g., a product, e.g., a drug unit dose or food) in amounts of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg). Terpene compounds can be present in a composition (e.g., a product, e.g., a drug unit dose or food) in amounts of about 50 to about 150 milligrams.Terpene compounds are present in compositions (e.g., products, e.g., drug unit doses or food) at a concentration of at least about 0.01% by weight, 0.02% by weight, 0.03% by weight, 0.04% by weight, 0.05% by weight, 0.06% by weight, 0.07% by weight, 0.08% by weight, 0.09% by weight, 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, and 0.8% by weight of the product. It can exist in amounts of 1%, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight. Terpene compounds are present in compositions (e.g., products, e.g., drug unit doses or food) at a maximum concentration of about 0.01% by weight, 0.02% by weight, 0.03% by weight, 0.04% by weight, 0.05% by weight, 0.06% by weight, 0.07% by weight, 0.08% by weight, 0.09% by weight, 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, and 0.8% by weight. It can exist in amounts of %, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight.Terpene compounds are present in compositions (e.g., products, e.g., drug unit doses or food) at concentrations of approximately 0.01% by weight, 0.02% by weight, 0.03% by weight, 0.04% by weight, 0.05% by weight, 0.06% by weight, 0.07% by weight, 0.08% by weight, 0.09% by weight, 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, and 0.8% by weight of the product. It can be present in amounts of 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight.

[0201] Non-cannabinoid therapeutic compounds may be present in a composition (e.g., product, e.g., drug unit dose or food) in amounts of at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg). Non-cannabinoid therapeutic compounds may be present in a composition (e.g., product, e.g., drug unit dose or food) in amounts of up to approximately 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg). Non-cannabinoid therapeutic compounds may be present in a composition (e.g., product, e.g., drug unit dose or food) in amounts of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg). Non-cannabinoid therapeutic compounds may be present in a composition (e.g., product, e.g., drug unit dose or food) in amounts of about 50 to about 150 milligrams.Non-cannabinoid therapeutic compounds contain at least about 0.01% by weight, 0.02% by weight, 0.03% by weight, 0.04% by weight, 0.05% by weight, 0.06% by weight, 0.07% by weight, 0.08% by weight, 0.09% by weight, 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0. It can exist in amounts of 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight. Non-cannabinoid therapeutic compounds are present in compositions (e.g., products, drug unit doses, or foods) at a maximum concentration of approximately 0.01% by weight, 0.02% by weight, 0.03% by weight, 0.04% by weight, 0.05% by weight, 0.06% by weight, 0.07% by weight, 0.08% by weight, 0.09% by weight, 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, and 0. It can exist in amounts of 8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight.Non-cannabinoid therapeutic compounds are present in compositions (e.g., products, e.g., drug unit doses or foods) at concentrations of approximately 0.01% by weight, 0.02% by weight, 0.03% by weight, 0.04% by weight, 0.05% by weight, 0.06% by weight, 0.07% by weight, 0.08% by weight, 0.09% by weight, 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, and 0.8% by weight of the product. It can exist in amounts of weight %, 0.9 weight%, 1 weight%, 2 weight%, 3 weight%, 4 weight%, 5 weight%, 6 weight%, 7 weight%, 8 weight%, 9 weight%, 10 weight%, 11 weight%, 12 weight%, 13 weight%, 14 weight%, 15 weight%, 16 weight%, 17 weight%, 18 weight%, 19 weight%, 20 weight%, 25 weight%, 30 weight%, 35 weight%, 40 weight%, 45 weight%, or 50 weight%.

[0202] For the compositions disclosed herein, the amount of cannabinoid compounds is at least about 0.01% by weight, 0.02% by weight, 0.03% by weight, 0.04% by weight, 0.05% by weight, 0.06% by weight, 0.07% by weight, 0.08% by weight, 0.09% by weight, 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, and 8% by weight. %, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, 50% by weight, 60% by weight, 70% by weight, 80% by weight, 90% by weight, 100% by weight, 200% by weight, 300% by weight, 400% by weight, 500% by weight, 600% by weight, 700% by weight, 800% by weight, 900% by weight, 1,000% by weight, 2,000% by weight, or more. For the compositions disclosed herein, the amount of cannabinoid compounds is, at most, about 0.01% by weight, 0.02% by weight, 0.03% by weight, 0.04% by weight, 0.05% by weight, 0.06% by weight, 0.07% by weight, 0.08% by weight, 0.09% by weight, 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, and 8% by weight. 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, 50% by weight, 60% by weight, 70% by weight, 80% by weight, 90% by weight, 100% by weight, 200% by weight, 300% by weight, 400% by weight, 500% by weight, 600% by weight, 700% by weight, 800% by weight, 900% by weight, 1,000% by weight, 2,000% by weight, or more.

[0203] For the compositions disclosed herein, the amount of cannabinoid compounds is at least about 0.01% by weight, 0.02% by weight, 0.03% by weight, 0.04% by weight, 0.05% by weight, 0.06% by weight, 0.07% by weight, 0.08% by weight, 0.09% by weight, 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, and 8% by weight. %, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, 50% by weight, 60% by weight, 70% by weight, 80% by weight, 90% by weight, 100% by weight, 200% by weight, 300% by weight, 400% by weight, 500% by weight, 600% by weight, 700% by weight, 800% by weight, 900% by weight, 1,000% by weight, 2,000% by weight, or more, and less. For the compositions disclosed herein, the amount of cannabinoid compounds is, at most, about 0.01% by weight, 0.02% by weight, 0.03% by weight, 0.04% by weight, 0.05% by weight, 0.06% by weight, 0.07% by weight, 0.08% by weight, 0.09% by weight, 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, and 8% by weight. 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, 50% by weight, 60% by weight, 70% by weight, 80% by weight, 90% by weight, 100% by weight, 200% by weight, 300% by weight, 400% by weight, 500% by weight, 600% by weight, 700% by weight, 800% by weight, 900% by weight, 1,000% by weight, 2,000% by weight, or more, and less.

[0204] In some cases, the amount of the cannabinoid compound may be approximately the same as the amount of the non-cannabinoid therapeutic compound in the compositions disclosed herein.

[0205] The encapsulated noncannabinoid therapeutic compound may be present in amounts of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 nanograms, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule. Encapsulated non-cannabinoid therapeutic compounds can be present in amounts of up to approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 nanograms per microcapsule, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms. Encapsulated non-cannabinoid therapeutic compounds can be present in amounts of approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 nanograms, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule. Encapsulated non-cannabinoid therapeutic compounds can be present in amounts of approximately 1 to approximately 10 micrograms per microcapsule.The encapsulated noncannabinoid therapeutic compound may be present in the microcapsule in amounts of at least about 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight. Encapsulated noncannabinoid therapeutic compounds can be present in microcapsules in amounts of up to approximately 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight. The encapsulated noncannabinoid therapeutic compound may be present in amounts of approximately 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, or 50% by weight of the microcapsule.

[0206] The compositions of this disclosure may be enriched with cannabinoids compared to hemp oil. For example, a composition may include hemp oil and cannabinoids from plant sources such as extracts (e.g., hemp extract) and essential oils. A composition may contain cannabinoids at concentrations about 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000% higher than hemp oil.

[0207] The compositions of this disclosure may be enriched with cannabidiol compounds compared to hemp oil. For example, a composition may include hemp oil and cannabidiol compounds from plant sources such as extracts (e.g., hemp extract) and essential oils. A composition may contain cannabidiol compounds at concentrations about 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000% higher compared to hemp oil.

[0208] The compositions of this disclosure may be enriched with THC compounds compared to hemp oil. For example, a composition may include hemp oil and THC compounds from plant sources such as extracts (e.g., hemp extract) and essential oils. A composition may contain THC compounds at concentrations about 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000% higher compared to hemp oil.

[0209] The compositions of this disclosure may be enriched with terpenes compared to hemp oil. For example, a composition may include hemp oil and terpenes from plant sources such as extracts (e.g., hemp extract) and essential oils. The compositions may contain terpenes at concentrations about 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000% higher compared to hemp oil.

[0210] The compounds contained in the compositions of this disclosure may be derived from a variety of sources. Compound sources may be natural products, such as plant extracts or essential oils. Compounds in the compositions of this disclosure may be derived from hemp oil containing cannabinoid compounds, THC compounds, and terpene compounds. Compounds in the compositions of this disclosure may be derived from essential oils, including but not limited to those discussed further in this disclosure. These compounds may contain cannabinoid compounds and terpene compounds. In some cases, all compounds or components in the compositions are natural or of natural origin. In some cases, all compounds or components in the compositions are vegetarian. In some cases, all compounds or components in the compositions are vegan.

[0211] The terpenes and / or essential oils in the compositions of this disclosure may be selected to provide benefits for a particular condition or subject. Terpenes and / or essential oils may be used in combination with each other and in combination with cannabinoids to target, for example, the treatment of a particular condition. For example, terpinolenes, terpineols and linalools or lavender, valerian and jasmine essential oils may be combined with cannabinoids or cannabis extracts to act as sleep aids or to treat sleep disorders.

[0212] Alpha-pinene can be used as an anti-inflammatory agent, anti-angiogenic agent, anti-ulcer agent, and bronchodilator.

[0213] Linalool can be used as a sedative, analgesic, antimicrobial, antibacterial, and anticonvulsant to improve Alzheimer's disease or its symptoms by reducing anxiety and inflammation (e.g., lung inflammation).

[0214] Myrcene can be used as an antibacterial agent, neuroprotective agent, antinociceptive agent, and analgesic, as well as to alleviate neuropathic pain, peptic ulcers, and inflammation. Depending on the concentration, myrcene can be used as a sedative (e.g., myrcene above 0.5%) or to provide an energy-boosting effect (e.g., myrcene below 0.5%).

[0215] Limonene can be used to reduce anxiety and depression, dissolve cholesterol-containing gallstones, neutralize stomach acid, support normal peristalsis, relieve heartburn and gastroesophageal reflux, improve immune function, and as a chemopreventive agent against cancer.

[0216] Ocimen can be used as an antifungal, antitumor, and cytotoxic agent.

[0217] Terpinolene can be used for its antioxidant, mood-regulating, central nervous system (CNS) modulating, anti-inflammatory, antidiarrheal, antifilariatic, antifungal, antimalarial, anti-amebic, antibacterial, cytotoxic, and anticancer effects.

[0218] Terpineol can be used to relax the subject, aid digestion, improve gastrointestinal disorders, and relieve influenza, bronchitis, cough, nasal congestion, and sinusitis.

[0219] Beta-caryophyllene can be used as an anti-inflammatory, antitumor, and analgesic agent.

[0220] Geraniol can be used as an antidepressant to reduce or prevent neuropathy, as an anti-angiogenic agent, as an anticancer agent to improve the efficacy of anticancer drugs, as an antioxidant to inhibit the growth of cancer cells (e.g., lung cancer), as a chemopreventive agent against cancer, as an anti-inflammatory and apoptotic agent to reduce inflammation and apoptosis (e.g., in hepatocytes), as an antioxidant to reduce oxidative stress, and as an antimicrobial agent.

[0221] Alpha-humulene can be used as an appetite suppressant, anti-inflammatory agent, insecticide, antibacterial agent, antioxidant, and allelopathic substance.

[0222] Phellandrene can be used as an antidepressant and analgesic.

[0223] Karen can be used as an antioxidant, antiproliferative agent, and antimicrobial agent, and to reduce the production of excess bodily fluids such as tears, mucus, or sweat.

[0224] Terpinene can be used as an antioxidant, anti-inflammatory, antimicrobial, and antiproliferative agent to reduce oxidative stress and to manage diabetes.

[0225] Fencol can be used as an antibacterial agent, anti-mycobacterial agent, antimicrobial agent, and antioxidant.

[0226] Borneol can be used as a TRPA1 inhibitor, anti-inflammatory agent, and antinociceptor to reduce hyperalgesia.

[0227] Bisabolol can be used as an anticancer agent (for example, to induce apoptosis in leukemia), an antitumor agent (for example, pancreatic cancer), and an antigenotoxic agent.

[0228] Phytol can be used to relax subjects by inhibiting the breakdown of GABA, as an anxiety reliever, to suppress menadione-induced oxidative stress, and as an antimicrobial agent.

[0229] Camphene can be used as an antioxidant for pain relief, as an antitumor agent to induce apoptosis in cancer cells (e.g., melanoma), and as an antibacterial agent.

[0230] Sabinen can be used as an antioxidant, an antimicrobial agent, an anticancer agent (e.g., oral, liver, lung, colon, melanoma, and leukemia cancers), to assist liver function, aid digestion, relieve arthritis, and relieve skin conditions.

[0231] Camphor can be used as a local anesthetic, a muscle relaxant, an anti-pathogenic agent, and an antimicrobial agent to improve skin healing (e.g., reconstructed human epithelium).

[0232] Isoborneol can be used as an antioxidant, a cytotoxic agent, a DNA protecting agent, to inhibit herpes simplex virus type 1, and to inhibit HIV.

[0233] Menthol can be used as an analgesic, to desensitize the α3β4 nicotinic acetylcholine receptor, as an anti-nociceptive agent, and as an anti-inflammatory agent.

[0234] Nerolidol can be used as an antifungal agent, an antimicrobial agent, an antioxidant, and an antimalarial agent.

[0235] Guaiol can be used as an antimicrobial agent, an antifungal agent, and an antibiotic.

[0236] Isopregol can be used as a gastric protectant, an anti-inflammatory agent, to enhance the permeability for transdermal administration of compounds, and to reduce the severity of seizures.

[0237] Geranyl acetate can be used as an antimicrobial agent, an antibacterial agent, and an antioxidant.

[0238] Cymene can be used as an anti-inflammatory agent, an anti-hyperalgesic agent, an antioxidant, an anti-diabetic agent, to assist in weight loss, to assist in immune disorders, and to prevent acute lung injury.

[0239] Eucalyptol can be used as an antifungal agent, an antioxidant to reduce inflammation (e.g., lung inflammation), and an anticancer agent.

[0240] Pulegone can be used as an insecticide and antioxidant to enhance skin penetration.

[0241] The compositions of this disclosure appear to include one or more essential oils or essential oil compounds. As essential oils, these are not limited to: linalool; β-caryophyllene; β-myrcene; D-limonene; humulene; α-pinene; ylang-ylang (Cananga odorata); yarrow (Achillea millefolium); violet (Viola odorata); vetiver (Vetiveria zizanoides); vanilla (Vanilla plantifolia); tuberose (Polianthes tuberosa); thyme (Thymus vulgaris L.); tea tree (Melaleuca alternifolia); tangerine (Citrus reticulata); black spruce (Picea mariana); spruce (Tsuga Canadensis); citronella (Nardostachys jatamansi); spruce (Mentha spicata); sandalwood (Santalum spicatum); rosewood (Aniba rosaeodora); rosemary verbenone (Rosmarinus Rosemary (Rosmarinus officinalis); Rose (Rosa damascena); Baby ginger (Pelargonium roseum); Ravensara (Ravensara aromatica); Ply (Zingiber cassumunar); Pine grass (Pinus sylvestris L.); Petitgrain (Citrus aurantium); Peppermint (Mentha piperita); Black pepper (Piper nigrum L.)); Patchouli (Pogostemon cablin); Palo Santo (Bursera graveolens); Palmarosa (Cymbopogon martini); Osmanthus fragrans; Oregano (Origanum vulgare); Sweet Orange (Citrus sinensis); Oakmoss (Evernia prunastri); Nutmeg (Myristica fragrans); Niaouli (Melaleuca viridifloria); Neroli (also known as Orange Blossom) (Citrus aurantium); Myrtle (Myrtus communis); Myrrh (Commiphora. myrrha); mimosa (Acacia decurrens); melissa (Melissa officinalis L.); sweet marjoram (Origanum majorana); manuka (Leptospermum scoparium); red mandarin (Citrus deliciosa); mandarin (Citrus deliciosa); white lotus (Nelumbo nucifera); pink lotus (Nelumbo nucifera); blue lotus (Nelumbo nucifera); lime (Citrus aurantifolia); lily (Lilum) aurantum); lemongrass (Cymbopogon citratus); lemon (Citrus limonum); lavender (Lavandula angustifolium); lavandin (Lavandula hybrida grosso); kanuka (Kunzea ericoides); juniper berry (Juniperus cummunis); jasmine (Jasminum officinale); jasmine abs (Jasminum sambac); strawflower (Helichrysum italicum); white grapefruit (Citrus x paradisi); pink grapefruit (Citrus paradisi); ginger (Zingiber officinalis); geranium (Pelargonium) graveolens); Bourbon geranium (Pelargonium graveolens, 'Herit'); Gardenia jasminoides; Galbanum (Ferula galbaniflua); Frankincense (Boswellia carterii); Frangipani (Plumeria alba); White fir needle (Abies alba); Siberian fir needle (Abies siberica); Canadian fir needle (Abies balsamea); Sweet fennel (Foeniculum vulgare); Eucalyptus Smithii, Eucalyptus Radiata, Eucalyptus Globulus, Eucalyptus Citriodora, Eucalyptus Blue Mallee (Eucalyptus polybractea); Elemi (Canarium luzonicum); Dill (Anethum graveolens); Cypress (Cupressus sempervirens); Cumin (Cuminum cyminum); Coriander (Coriandum) sativum; cocoa (Theobroma cacao); clove (Eugenia caryophylatta); clary sage (Salvia sclarea); cistus (also known as Labdanum) (Cistus ladaniferus L.); cinnamon (Cinnamomum zeylanicum); Roman chamomile (Anthemis nobilis); blue chamomile (Matricaria chamomilla); celery seeds (Apium graveolins); Western red cedar (Thuja plicata); cedarwood, blood (Juniperus virginiana); cedarwood atlas (Cedrus atlantica); carrot seeds (Daucus Examples include carota; cardamom (Elettaria cardamomum); caraway seeds (Carum carvi); cajaputi (Melaleuca cajuputi); caddisfly (Juniperus oxycedrus); American white birch (Betula alba); American birch (Betula lenta); bergamot (Citrus bergamia); bay laurel (Laurus nobilis); basil (Ocimum basilicum); oak sanctum (Ocimum sanctum); basil (Ocimum basilicum); balsam poplar (Populus balsamifera); balsam Peru (Myroxylon balsamum); angelica (Angelica archangelica L.); and combinations thereof.

[0242] The compositions of this disclosure may include, but are not limited to, one or more additional ingredients including mushrooms or mushroom derivatives (e.g., Reishi, Chaga, Maitake, Oyster mushroom, Oriental tomentosa), maca (Lepidium meyenii), Polygonum multiflorum (also known as he show wu or shou wu chih), superfoods or superfood derivatives (e.g., blueberries, acai berries, Inca berries, goji berries, camu camu, coconut, lucuma, kale, cacao (e.g., cacao powder, cacao butter), sacha inchi, chia, flax, hemp, amaranth, quinoa, moringa oleifera), and combinations thereof.

[0243] The compounds used in the compositions of this disclosure can be extracted by a variety of methods. For example, extraction can be carried out by maceration, injection, decoction, leaching, Soxhlet extraction, pressurized solvent extraction, countercurrent extraction, sonication, or supercritical fluid (e.g., carbon dioxide) extraction.

[0244] In some cases, the compounds used in the compositions of this disclosure are extracted via supercritical fluid (e.g., carbon dioxide) extraction. For example, cannabinoid compounds can be extracted from hemp (e.g., hemp stalks and stems) using supercritical carbon dioxide extraction.

[0245] The compositions of this disclosure may include pregnenolone, including its derivatives. Pregnenolone can help protect subjects from cannabis poisoning, such as THC. Pregnenolone or its derivatives may be formulated to be water-soluble. The compositions of this disclosure may contain pregnenolone or its derivatives in amounts between about 1 and 50 milligrams (mg). For example, the unit dose of this disclosure may contain pregnenolone in amounts between about 1 and 50 milligrams (mg). The compositions of this disclosure (e.g., unit doses) may contain about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 mg of pregnenolone. A composition of the present disclosure (e.g., a unit dose) may contain at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 mg of pregnenolone. A composition of the present disclosure (e.g., a unit dose) may contain up to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 mg of pregnenolone. A composition containing pregnenolone may be used in combination with any other compounds, components, or formulations described herein, including esters, cyclodextrin complexes, microcapsules (e.g., sodium alginate microcapsules), immediate-release formulations, delayed or extended-release formulations, transchoucho formulations, and sublingual formulations.

[0246] The compositions disclosed herein are used to treat conditions in subjects (e.g., humans, mammals, vertebrates) such as ALS, Alzheimer's disease, antibiotic-resistant infections, anxiety, atherosclerosis, arthritis, asthma, cancer, colitis, Crohn's disease, diabetes, depression, endocrine disorders, epilepsy, seizures, fibromyalgia, glaucoma, heart disease, Huntington's disease, inflammation, irritable bowel syndrome (IBS), kidney disease, liver disease, motion sickness, nausea, neurodegeneration, neuropathic pain, neuropathy, obesity, These compositions can be used to treat a variety of diseases or conditions, including but not limited to obsessive-compulsive disorder (OCD), osteoporosis, Parkinson's disease, prion diseases, mad cow disease, post-traumatic stress disorder (PTSD), rheumatism, schizophrenia, sickle cell anemia, skin conditions (e.g., psoriasis, dermatitis, allergic inflammation, chronic pruritus), sleep disorders (e.g., sleep-wake disorder, apnea), spinal cord injury, stress, stroke, and traumatic brain injury (TBI). The compositions of this disclosure can be provided as dry powders. For example, an oil-based composition (e.g., hemp oil) can be combined with a drying or powdering agent such as cyclodextrin. In some cases, a powder composition can be provided on its own. In other cases, a powder composition can be provided in other products such as foods, cosmetics, or other products and compositions disclosed herein.

[0247] The compositions of this disclosure may be provided in any suitable form, including but not limited to liquid form, gel form, semi-liquid form (e.g., a liquid such as a viscous liquid containing some solid), semi-solid form (a solid containing some liquid), or solid form. The compositions may be provided, for example, in tablet form, capsule form, food form, chewable form, non-chewable form, transchucral form, sublingual form, slow-release form, non-slow-release form, sustained-release form, or non-sustained-release form.

[0248] The compositions of this disclosure can be administered in any oral dosage form, including liquid dosage forms (e.g., suspensions or slurries) and oral solid dosage forms (e.g., tablets or bulk powders). Tablets may include tablets, caplets, capsules including soft gelatin capsules, and lozenges. Tablets may further contain suitable binders, lubricants, diluents, disintegrants, colorants, flavorings, flow inducers, and melting agents.

[0249] The compositions of the present disclosure can be administered transdermally, for example, via a patch. The compositions of the present disclosure can be administered intravenously. The compositions of the present disclosure can be administered topically. The compositions of the present disclosure can be administered by exposure to an aqueous solution, such as by immersing a subject in a float tank. The compositions of the present disclosure can be formulated as bath salts or liquid bath products that can be dissolved or dispersed in water (e.g., a bathtub) for skin exposure, for example, by immersion of a subject.

[0250] The compositions of this disclosure can be provided as cosmetic or personal care products, such as soaps (e.g., solid, bar, liquid, or foam), hand sanitizers, lotions, massage oil masks, makeup, moisturizers, sunscreens, toothpastes, mouthwashes, or throat sprays. The use of cannabinoids in such applications can provide benefits, including the reduction of inflammation in the subject.

[0251] The compositions of this disclosure may be provided in combination with a food carrier as a food composition including, but not limited to, food bars (e.g., granola bars, protein bars, candy bars), cereal products (e.g., oatmeal, breakfast cereals, granola), bakery products (e.g., bread, donuts, crackers, bagels, pastries, cakes), dairy products (e.g., milk, yogurt, cheese), beverages (e.g., milk-based beverages, sports drinks, fruit juices, tea, soft drinks, alcoholic beverages, milk water), mixed drinks, pasta, grains (e.g., rice, corn, oats, rye, wheat, flour), egg products, snacks (e.g., candy, chips, gum, gummies, lozenges, mints, chocolate), meat, fruits, vegetables, or combinations thereof. The food composition may include solid foods. The food composition may include semi-solid foods. The food composition may include liquid foods. Compositions in liquid form may be formulated from dry mixes, such as dry beverage mixes or powders. Dry mixes may be suitable with respect to transport, storage, or shelf life. The composition can be formulated from the dry mix in any suitable way, for example, by adding a suitable liquid (e.g., water, milk, fruit juice, tea, or alcohol).

[0252] Food compositions or foods may include food bars, including but not limited to granola bars, protein bars, candy bars, and energy bars. Food compositions or foods may include cereal products, including but not limited to oatmeal, grain flours (e.g., wheat flour, rice flour, corn flour, barley flour), breakfast cereals, granola, bread, pasta, mochi, and popcorn. Food compositions or foods may include bakery products, including but not limited to bread, pastries, brownies, cakes, pies, donuts, crackers, and muffins. Food compositions or foods may include dairy products, including but not limited to milk, fermented milk, curd, whey, yogurt, cream, cheese, butter, clear butter, ghee, and ice cream. Food compositions or foods may include nut butter or seed butter, including but not limited to peanut butter, almond butter, cashew butter, hazelnut butter, macadamia nut butter, pecan butter, pistachio butter, walnut butter, pumpkin seed butter, sesame seed butter, soybean butter, and sunflower seed butter. Food compositions or foods may include, but are not limited to, oils such as olive oil, coconut oil, vegetable oil, canola oil, corn oil, peanut oil, sunflower seed oil, almond oil, avocado oil, rice bran oil, cottonseed oil, flaxseed oil, linseed oil, grape seed oil, hemp oil, mustard oil, macadamia oil, palm oil, tea oil, walnut oil, margarine, lard, butter, clear butter, ghee, or taro (e.g., cooking oil). Food compositions or foods may also include sports foods such as energy gels, sports drinks, energy powders, energy bars, energy shots, protein powders, and protein drinks (e.g., protein shakes).Food compositions or foods may include, but are not limited to, beverages such as water, electrolyte drinks, soda, coconut water, tea (e.g., jun tea, black tea, green tea, white tea, herbal tea), coffee, soft drinks, alcoholic beverages (e.g., cocktails, liquor, spirits, beer, wine, malt drinks), water, juices (e.g., apple juice, orange juice, tomato juice, vegetable juice, cranberry juice), sports drinks, electrolyte-rich water, vitamin-rich water, hangover remedies, milk (e.g., dairy-based milk, coconut milk, almond milk, soy milk, hemp milk, rice milk, oat milk, cashew milk, hazelnut milk), and yogurt. Food compositions or foods may include, but are not limited to, fungal or fermented foods or beverages such as kefir, jun, amasi, amazake, appa, ayran, dougu, bagoong, brum, cheonggukjang, chicha, kombucha, fermented tofu, kimchi, lassi, miso, poi, yakult, and yogurt.

[0253] The compositions of this disclosure may include pet or other animal products, such as animal foods (e.g., dog food, cat food), treats, and nutritional supplements (e.g., liquids, sprays, or powders to be applied to food or water). These compositions may be formulated or administered for household or pet animals (e.g., dogs, cats, small animals, birds), livestock and other farm animals (e.g., cattle, pigs, horses, sheep, goats), zoo animals, or any other vertebrate animals. Compositions for administration to animals may be formulated with microencapsulated or unencapsulated cannabinoid-rich oils, alone or in combination with essential oils, terpenes, and other components described herein. Compositions for administration to animals may be mixed with feed or water, prepared for spray application (e.g., mixed with glycerin), for intravenous administration (e.g., in syringes or IV bags), in the form of ointments, vitamins, liquid vitamin pumps, treats, or other forms.

[0254] The compositions of the present disclosure can include one or more additional agents, whether active or passive. Examples of such agents include sweeteners, flavoring agents, coloring agents, fillers, binders, lubricants, excipients, preservatives, or manufacturing agents. Pharmaceutically acceptable additional excipients (in the case of pharmaceuticals) or other additives (in the case of non-pharmaceutical applications) can be added to the compositions. For example, if desired, any generally acceptable soluble or insoluble inert pharmaceutical filler (diluent) material can be included in the final product (e.g., solid dosage form). Such inert pharmaceutical fillers can include monosaccharides, disaccharides, polyhydric alcohols, inorganic phosphates, sulfates or carbonates, and combinations thereof. Examples of suitable inert pharmaceutical fillers include sucrose, dextrose, lactose, xylitol, fructose, sorbitol, calcium phosphate, calcium sulfate, calcium carbonate, microcrystalline cellulose, and combinations thereof. An effective amount of any generally acceptable pharmaceutical lubricant, such as calcium or magnesium stearate, can be added.

[0255] The compositions of the present disclosure can be administered to a subject. The compositions can be administered in a variety of ways including, but not limited to, oral and topical administration.

[0256] Administration of the compositions of the present disclosure to a subject can result in one or more beneficial effects. Beneficial effects can include, but are not limited to, pain relief, reduced bacterial growth, reduced blood glucose levels, improved blood lipid and cholesterol profiles, increased fat burning, reduced appetite, stimulated appetite, reduced vomiting or nausea, reduced seizures or spasms, antifungal effects, reduced inflammation, reduced arthritis (e.g., rheumatoid arthritis), reduced insomnia or supported sleep, reduced arterial occlusion, inhibited cancer cell growth, improved psoriasis, calming effects, antispasmodic effects, reduced anxiety, promotion of bone growth, reduced intestinal contractions, and neuroprotection.

[0257] Administration of the compositions of this disclosure to a subject may improve the therapeutic range of the subject. The improved therapeutic range may be compared to the individual administration of noncannabinoid therapeutic compounds. Administration of the compositions of this disclosure may reduce the toxicity of noncannabinoid therapeutic compounds compared to the individual administration of noncannabinoid therapeutic compounds.

[0258] Any of the compositions in question can be provided as a unit dosage form. A unit dosage is the amount of a compound, such as a cannabinoid compound, delivered together with other components (e.g., non-cannabinoid therapeutic compounds disclosed herein) to the subject at one or nearly one time point (e.g., orally, intravenously, etc.). Other components that may be included with the unit dosage include, but are not limited to, cosmetics, food carriers, food bars, baked goods, dairy products, oils, beverages, solid medications (e.g., tablets or pills), or liquid medications. A unit dosage of a cannabinoid compound may be about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000 or more milligrams (mg). The unit dose of a cannabinoid compound may be at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000 or more milligrams (mg). The unit dose of a cannabinoid compound may be up to about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000 or more milligrams (mg). The unit dose of non-cannabinoid therapeutic compounds may be at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000 or more milligrams (mg). The unit dose of non-cannabinoid therapeutic compounds may be at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000 or more milligrams (mg).The unit dose of a non-cannabinoid therapeutic compound may be up to approximately 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000 or more milligrams (mg). The unit dose may be the dose per hour. The unit dose may be the dose per day. The unit dose may provide approximately 1 / 24, 1 / 12, 1 / 8, 1 / 6, 1 / 4, 1 / 3, 1 / 2, or all of the daily dose of one or more cannabinoids or at least one non-cannabinoid therapeutic compound for the subject. A unit dose may be in the form of a tablet, gel, liquid, food, food bar, container of liquid of a specified volume, or other form as described herein, packaged for single consumption or administration.

[0259] The compositions described herein can offer several advantages, including but not limited to increased storage stability, increased bioavailability, increased biological activity, and delayed release. When administered to a subject, the compositions described herein may have a variety of release profiles, half-lives, and metabolic properties. The composition in question may contain a plurality of microcapsules, each of which is characterized by exhibiting at least one of the following: (a) an S-shaped release profile of at least one cannabinoid compound; (b) a plasma half-life of at least one cannabinoid compound that is more than twice as long as that of at least one cannabinoid compound not in encapsulated form; (c) a first-pass metabolism of at least one cannabinoid compound that is reduced by at least 50% compared to at least one cannabinoid compound not in encapsulated form; (d) an elimination rate of at least one cannabinoid compound from the subject's body that is reduced by at least 20% compared to at least one cannabinoid compound not in encapsulated form; or (e) a degradation rate of at least one cannabinoid compound at an ambient temperature of at least 20°C that is less than about 50% of the degradation rate of at least one cannabinoid compound not in encapsulated form.

[0260] The compositions described herein may have a storage half-life of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 240, 270, 300, 330, or 360 days. In some cases, the compositions described herein may have a storage half-life of at least about 1, 2, 3, 4, or 5 years. Compositions in microencapsulated form may be characterized by a cannabinoid degradation rate at an ambient temperature of at least 20°C that is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% lower than the degradation rate of unencapsulated cannabinoid compositions.

[0261] Microencapsulated cannabinoid compositions may be characterized by their plasma half-lives in a target at least about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.5, 4.0, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, or 100 times that of unencapsulated cannabinoid compositions. The plasma half-life of a composition can be experimentally determined by administering the composition to a subject, taking plasma samples from the subject at multiple time points, and measuring the concentration of one or more compounds of interest in those plasma samples. The concentration of one or more compounds of interest will reach a peak value in the plasma and then decrease as one or more compounds are metabolized, broken down, or removed from the bloodstream. The plasma half-life is the time it takes for the plasma concentration to be halved.

[0262] The cannabinoid release profile can be S-shaped (e.g., having an "S"-shaped curve such as a logistic function). The cannabinoid release profile can be non-S-shaped. The cannabinoid release profile can be linear. The cannabinoid release profile can be non-linear. The cannabinoid release profile can be instantaneous. The cannabinoid release profile can be non-instantaneous. The cannabinoid release profile can be delayed. The cannabinoid release profile can be constant or sustained. The cannabinoid release profile can be variable or non-sustained.

[0263] Tablets can be formulated in a sustained-release format. Various methods exist for producing sustained-release tablets; see, for example, U.S. Patent Application Publication 2006 / 0051416 and U.S. Patent Application Publication 2007 / 0065512, which are incorporated herein by reference in their entirety. An example of a gradual-release tablet is provided in U.S. Patent No. 3,456,049, which is incorporated herein by reference in its entirety. Slow-release or sustained-release forms can delay the disintegration or absorption of the composition or one or more of its components.

[0264] In some cases, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or less of the cannabinoid compound is released from the microcapsules within one hour of administration to the subject. In some cases, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or less of the cannabinoid compound is released from the microcapsules within two hours of administration to the subject. In some cases, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or less of the cannabinoid compound is released from the microcapsules within 3 hours of administration to the subject. In some cases, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or less of the cannabinoid compound is released from the microcapsules within 4 hours of administration to the subject. In some cases, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or less of the cannabinoid compound is released from the microcapsules within 5 hours of administration to the subject. In some cases, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or less of the cannabinoid compound is released from the microcapsules within 6 hours of administration to the subject.In some cases, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or less of the cannabinoid compound is released from the microcapsules within 7 hours of administration to the subject. In some cases, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or less of the cannabinoid compound is released from the microcapsules within 8 hours of administration to the subject.

[0265] The release profile is the relationship between time and the amount of compound released into a target or the concentration of the compound within the target (e.g., in plasma). The release profile can be measured using a method similar to that of plasma half-life. The composition can be administered to a target, and samples (e.g., plasma or blood samples) can be taken from the target at multiple time points. The concentration of one or more compounds of interest can be measured in such samples, and the release profile can be plotted.

[0266] Compounds ingested by a subject via the gastrointestinal system are transported to the liver and can then enter the systemic circulation. Compounds that are readily metabolized and broken down in the liver may have substantially reduced activity due to first-pass metabolism through the liver. Encapsulation of compounds (e.g., microencapsulation) can reduce the first-pass metabolism of compounds in the liver. Compositions in microencapsulated form may be characterized by first-pass metabolism in subjects at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% less than that of unencapsulated cannabinoid compositions. Compositions in microencapsulated form may be characterized by a cannabinoid efflux rate from a subject that is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% less than that of unencapsulated cannabinoid compositions.

[0267] The compositions described herein may have improved bioavailability, bioactivity, or both when administered to a subject. Bioavailability is the proportion of the administered dose of the unchanged compound that reaches systemic circulation. Microencapsulated cannabinoid compositions may be characterized by bioavailability in a subject at least 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10.0 times greater than that of unencapsulated cannabinoid compositions. Cannabinoid compositions in microencapsulated form may be characterized by their bioavailability in at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of the target. Bioactivity, or biological activity, is the activity mediated by one or more active components in the composition. Microencapsulated cannabinoid compositions may be characterized by their bioavailability in subjects at least 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10.0 times that of unencapsulated cannabinoid compositions.

[0268] The composition in question may comprise a plurality of microcapsules, each of which is characterized by exhibiting at least one of the following: (a) an S-shaped release profile of at least one noncannabinoid therapeutic compound; (b) a plasma half-life of at least one noncannabinoid therapeutic compound that is more than twice the plasma half-life of at least one noncannabinoid therapeutic compound not in encapsulated form; (c) a first-pass metabolism of at least one noncannabinoid therapeutic compound that is reduced by at least 50% compared to at least one noncannabinoid therapeutic compound not in encapsulated form; (d) an elimination rate of at least one noncannabinoid therapeutic compound from the subject's body that is reduced by at least 20% compared to at least one noncannabinoid therapeutic compound not in encapsulated form; or (e) a degradation rate of at least one noncannabinoid therapeutic compound at an ambient temperature of at least 20°C that is less than about 50% of the degradation rate of at least one noncannabinoid therapeutic compound not in encapsulated form.

[0269] The compositions described herein may have a storage half-life of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 240, 270, 300, 330, or 360 days. In some cases, the compositions described herein may have a storage half-life of at least about 1, 2, 3, 4, or 5 years. Compositions in microencapsulated form can be characterized by a degradation rate of noncannabinoid therapeutic compounds that is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% lower than that of unencapsulated noncannabinoid therapeutic compounds at an ambient temperature of at least 20°C.

[0270] Microencapsulated noncannabinoid therapeutic compounds can be characterized by a plasma half-life in the subject that is at least about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.5, 4.0, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, or 100 times greater than that of unencapsulated noncannabinoid therapeutic compounds in the subject.

[0271] The release profile of a non-cannabinoid therapeutic compound may be S-shaped (e.g., having an "S"-shaped curve such as a logistic function). The release profile of a non-cannabinoid therapeutic compound may be non-S-shaped. The release profile of a non-cannabinoid therapeutic compound may be linear. The release profile of a non-cannabinoid therapeutic compound may be non-linear. The release profile of a non-cannabinoid therapeutic compound may be instantaneous release. The release profile of a non-cannabinoid therapeutic compound may be non-instantaneous release. The release profile of a non-cannabinoid therapeutic compound may be delayed release. The release profile of a non-cannabinoid therapeutic compound may be constant or sustained release. The release profile of a non-cannabinoid therapeutic compound may be variable or non-sustained release.

[0272] In some cases, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or less of the non-cannabinoid therapeutic compound is released from the microcapsule within one hour of administration to the subject. In other cases, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or less of the non-cannabinoid therapeutic compound is released from the microcapsule within two hours of administration to the subject. In some cases, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or less of the non-cannabinoid therapeutic compound is released from the microcapsules within 3 hours of administration to the subject. In other cases, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or less of the non-cannabinoid therapeutic compound is released from the microcapsules within 4 hours of administration to the subject. In some cases, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or less of the non-cannabinoid therapeutic compound is released from the microcapsules within 5 hours of administration to the subject. In other cases, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or less of the non-cannabinoid therapeutic compound is released from the microcapsules within 6 hours of administration to the subject.In some cases, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or less of the non-cannabinoid therapeutic compound is released from the microcapsules within 7 hours of administration to the subject. In other cases, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or less of the non-cannabinoid therapeutic compound is released from the microcapsules within 8 hours of administration to the subject.

[0273] Encapsulation (e.g., microencapsulation) of non-cannabinoid therapeutic compounds can reduce the first-pass metabolism of the non-cannabinoid therapeutic compound in the liver. Microencapsulated non-cannabinoid therapeutic compounds can be characterized by a first-pass metabolism in the subject that is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% lower than that of unencapsulated non-cannabinoid therapeutic compounds in the subject. Microencapsulated noncannabinoid therapeutic compounds can be characterized by their elimination rate from the subject which is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% lower than the elimination rate of unencapsulated noncannabinoid therapeutic compounds from the subject.

[0274] Microencapsulated noncannabinoid therapeutic compounds can be characterized by a bioavailability in a subject that is at least 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10.0 times higher than the bioavailability of unencapsulated noncannabinoid therapeutic compounds in a subject. Microencapsulated noncannabinoid therapeutic compounds can be characterized by their bioavailability in the target area of ​​at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%. Microencapsulated noncannabinoid therapeutic compounds can be characterized by their bioactivity in the subject that is at least 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10.0 times higher than that of unencapsulated noncannabinoid therapeutic compounds in the subject.

[0275] The composition in question (for example, a drug composition in solid dosage form, such as a tablet or pill) may contain multiple cannabinoid compounds and multiple non-cannabinoids.

[0276] Compositions comprising non-cannabinoid therapeutic compounds and cannabinoid compounds can be characterized by the degradation rate of the non-cannabinoid therapeutic compound at an ambient temperature of at least 20°C, which is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% lower than the degradation rate of the cannabinoid compound at an ambient temperature of at least 20°C. Alternatively, the composition can be characterized by the degradation rate of a non-cannabinoid therapeutic compound at an ambient temperature of at least 20°C, which is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% higher than the degradation rate of a cannabinoid compound at an ambient temperature of at least 20°C. In yet another alternative, the degradation rates of the non-cannabinoid therapeutic compound and the cannabinoid compound may be substantially the same.

[0277] Compositions comprising non-cannabinoid therapeutic compounds and cannabinoid compounds can be characterized by a plasma half-life of the non-cannabinoid therapeutic compound in the subject that is at least about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.5, 4.0, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, or 100 times higher than the plasma half-life of the cannabinoid compound in the subject. Alternatively, a composition can be characterized by the plasma half-life of a non-cannabinoid therapeutic compound in a subject, which is at least about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.5, 4.0, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, or 1 / 100 of the plasma half-life of a cannabinoid therapeutic compound in a subject. In yet another alternative form, the plasma half-lives of the non-cannabinoid therapeutic compound and the plasma half-lives of the cannabinoid compound in a subject may be substantially the same.

[0278] Compositions comprising non-cannabinoid therapeutic compounds and cannabinoid compounds can be characterized by a release rate of the non-cannabinoid therapeutic compound that is at least about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.5, 4.0, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, or 100 times higher than that of the cannabinoid compound. Alternatively, the composition can be characterized by the release rate of a non-cannabinoid therapeutic compound at least about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.5, 4.0, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, or 1 / 100 of the release rate of the cannabinoid compound. In yet another alternative, the release rates of the non-cannabinoid therapeutic compound and the cannabinoid compound from the composition may be substantially the same.

[0279] Compositions comprising non-cannabinoid therapeutic compounds and cannabinoid compounds can be characterized by the first-pass metabolism of the non-cannabinoid therapeutic compound in the subject, which is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% higher than the first-pass metabolism of the cannabinoid compound in the subject. Alternatively, the composition can be characterized by the first-pass metabolism of the non-cannabinoid therapeutic compound in the subject, which is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% lower than the first-pass metabolism of the cannabinoid compound in the subject. In yet another alternative, the first-pass metabolism of the non-cannabinoid therapeutic compound and the first-pass metabolism of the cannabinoid compound in the subject may be substantially the same.

[0280] Compositions containing non-cannabinoid therapeutic compounds and cannabinoid compounds can be characterized by the elimination rate of the non-cannabinoid therapeutic compound in the subject being at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% higher than the elimination rate of the cannabinoid compound in the subject. Alternatively, the composition can be characterized by the elimination rate of the non-cannabinoid therapeutic compound in the subject, which is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% lower than the elimination rate of the cannabinoid compound in the subject. In yet another alternative, the elimination rates of the non-cannabinoid therapeutic compound and the cannabinoid compound in the subject may be substantially the same.

[0281] Compositions comprising non-cannabinoid therapeutic compounds and cannabinoid compounds can be characterized by the bioavailability of the non-cannabinoid therapeutic compound in the subject being at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% higher than the bioavailability of the cannabinoid compound in the subject. Alternatively, a composition can be characterized by the bioavailability of a non-cannabinoid therapeutic compound in the subject, which is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% lower than the bioavailability of a cannabinoid compound in the subject. In yet another alternative, the bioavailability of a non-cannabinoid therapeutic compound and the bioavailability of a cannabinoid compound in the subject may be substantially the same.

[0282] In some embodiments, the compositions disclosed herein may include a first composition comprising a non-cannabinoid therapeutic compound and a second composition comprising a cannabinoid therapeutic compound. The first and second compositions may be administered to a subject sequentially (e.g., one at a time) or simultaneously (e.g., all at once). The first and second compositions may be administered to a subject via the same route of administration (e.g., both orally) or via different routes of administration (e.g., one orally and the other intravenously).

[0283] In some cases, the first and second compositions disclosed herein may be administered to a subject sequentially (for example, via the same or different routes of administration). The administration of the first composition to a subject and the administration of the second composition to a subject may occur at intervals of at least about 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 16 hours, 20 hours, 24 hours, or longer. The administration of the first composition to the subject and the administration of the second composition to the subject may occur at intervals of up to approximately 24 hours, 20 hours, 16 hours, 12 hours, 11 hours, 10 hours, 9 hours, 8 hours, 7 hours, 6 hours, 5 hours, 4 hours, 3 hours, 2 hours, 1 hour, 50 minutes, 40 minutes, 30 minutes, 20 minutes, 15 minutes, 10 minutes, 5 minutes, 4 minutes, 3 minutes, 2 minutes, 1 minute, or shorter.

[0284] The subjects of this disclosure may include humans and other animals, such as pets (e.g., dogs, cats, birds, small animals, snakes) and livestock or farm animals (e.g., cattle, pigs, horses, sheep, chickens). The compositions of this disclosure can be used in veterinary applications.

[0285] The methods and systems of this disclosure can be used to form compositions for various uses, for example, to encapsulate compositions (e.g., therapeutic compositions). Examples of use of the methods of this disclosure are provided in WO2016 / 094810, which is incorporated herein by reference in its entirety. [Examples]

[0286] (Example 1) Microencapsulation of cannabinoids A hemp oil composition containing cannabinoids, including cannabidiol, is produced. Additional essential oils are added to the composition. Alginates (e.g., sodium alginate) and quillaja tree extracts are added to the composition. The composition is microencapsulated using a microfluidic nozzle device. Calcium chloride is used to crosslink the microcapsules. The microcapsules are packaged as a suspension, transported, and sold. (Example 2) Administration of cannabinoid compositions to the subject

[0287] A cannabinoid composition, such as the microencapsulated cannabinoid composition described in Example 1, is administered to a subject suffering from a condition associated with cannabinoid deficiency. The levels of cannabinoids in the subject increase, and their condition improves. (Example 3) Cannabidiol-rich hemp and coconut oil products

[0288] Cannabidiol compounds are enriched in hemp seed oil by adding extracts of hemp stems and stalks containing 10% to 40% by weight of cannabidiol compounds. The enriched hemp seed oil is blended with coconut oil to produce a final composition of cannabidiol compounds containing approximately 100 milligrams per 8 fl ounces of coconut oil. The coconut oil product is then used to produce consumer products, such as moisturizers, lotions, cooking oils, smoothies, spreads, and other foods. (Example 4) Cannabidiolic acid-rich hemp and coconut oil products

[0289] Cannabidiolic acid is enriched in hemp seed oil by adding hemp stem and stalk extracts containing 10% to 40% by weight of cannabidiolic acid. The enriched hemp seed oil is blended with coconut oil to produce a final composition of cannabidiolic acid containing approximately 100 milligrams per 8 fl ounces of coconut oil. The coconut oil product is then used to produce consumer products, such as moisturizers, lotions, cooking oils, smoothies, spreads, and other foods. (Example 5) Cannabidiol-rich hot chocolate mix

[0290] Cannabidiol-enriched hemp seed oil is made by adding hemp stem and stalk extracts containing 10% to 40% cannabidiol compounds. Next, the cannabidiol-rich hemp seed oil is combined with cyclodextrin (e.g., certified organic cyclodextrin) to form a dry powder. The hemp oil powder is mixed with powdered cocoa, cocoa butter mix, sweeteners, and, optionally, superfood products such as reishi mushroom powder, chaga mushroom powder, maca, or he shou wu. The mixture is packaged and sold as a chocolate beverage mix (e.g., hot chocolate mix). (Example 6) Production and packaging of cannabinoid-rich products

[0291] A standardized supercritical carbon dioxide extract is extracted from the stems and stalks of hemp. The extract (e.g., paste) is blended with hemp seed oil. The hemp extract and hemp oil blend is prepared with a THC content of less than 0.3% by weight and a CBD content of approximately 10–40% by weight. The hemp extract and hemp oil blend is further blended with coconut oil to provide approximately 100 mg of CBD per 8 ounces of coconut oil (approximately 423 mg per liter). The coconut oil blend containing CBD is packaged (e.g., in bottles) and sold to consumers. (Example 7) Administration of a pregnenolone composition to the subject.

[0292] A microencapsulated cannabinoid composition, as described in Example 1, further comprising a cannabinoid and a pregnenolone composition, such as pregnenolone (e.g., 1 to 50 mg of pregnenolone), is administered to a subject suffering from cannabinoid intoxication or addiction. The subject is protected from hyperactivation of CB1 receptors and their condition improves. (Example 8) Preparation of microencapsulated compositions

[0293] Formulations containing quillaja extract (e.g., Q Natural), hemp oil, water, and optionally sodium alginate were prepared using a microfluidic processor (e.g., a microfluidizer from Microfluidics / IDEX Corporation). The formulations were prepared as described in Table 11. Test 1 was prepared using 60 g of quillaja extract (e.g., Q Natural), 80 g of hemp oil, and 100 g of water in a microfluidic fluid processor at an operating pressure of 30,000 psi. Test 2 was prepared using 10 g of quillaja extract (e.g., Q Natural), 15 g of hemp oil, 198 g of water, and 2 g of sodium alginate in a microfluidic fluid processor at an operating pressure of 30,000 psi.

[0294] After processing with a microfluidic fluid processor, the particle size distribution was analyzed using a laser diffraction particle size analyzer (e.g., Horiba LA950). Optical microscope images were also taken.

[0295] Test 1 and Test 2 were each performed three times, and the particle size at the 10th percentile (D10), 50th percentile (D50), and 90th percentile (D90) were reported in Table 11. Particle size was also analyzed for the unprocessed solution (Test 1, 0th run). [Table 11]

[0296] Figure 1A shows a 400x magnification micrograph of the raw quillaja extract, hemp oil, and water composition (Test 1, 0th trial), with a scale bar of 50 μm. Figure 1B shows a 1000x magnification micrograph of the raw quillaja extract, hemp oil, and water composition (Test 1, 0th trial), with a scale bar of 50 μm.

[0297] Figure 2A shows a 400x magnification micrograph of the composition of quillaja extract, hemp oil, and water (Test 1, 1st time), with a scale bar of 50 μm. Figure 2B shows a 400x magnification micrograph of the composition of quillaja extract, hemp oil, and water (Test 1, 2nd time), with a scale bar of 50 μm. Figure 2C shows a 1000x magnification micrograph of the composition of quillaja extract, hemp oil, and water (Test 1, 2nd time), with a scale bar of 10 μm. Figure 2D shows a 1000x magnification micrograph of the composition of quillaja extract, hemp oil, and water (Test 1, 3rd time), with a scale bar of 10 μm.

[0298] Figure 3A shows a 1000x magnification micrograph of the composition of quillaja extract, hemp oil, water, and sodium alginate (Test 2, 1st time), with a scale bar of 10 μm. Figure 3B shows a 1000x magnification micrograph of the composition of quillaja extract, hemp oil, water, and sodium alginate (Test 2, 2nd time), with a scale bar of 10 μm. Figure 3C shows a 1000x magnification micrograph of the composition of quillaja extract, hemp oil, water, and sodium alginate (Test 2, 3rd time), with a scale bar of 10 μm. (Example 9) Administration of the combination therapy composition to the target

[0299] A microencapsulated cannabinoid composition as described in Example 1, further comprising a combination therapeutic composition, such as a non-cannabinoid therapeutic compound, is administered to a subject having or suspected to have a certain condition. Following administration, the subject is characterized by at least partial remission of the condition. For example, the subject may have cancer, and treatment using the combination therapeutic composition disclosed herein may at least partially treat the cancer (e.g., reduce the size of the subject's solid tumor). In another example, the subject may have a CNS disorder, and treatment using the combination therapeutic composition disclosed herein may at least partially treat the CNS disorder. (Example 10) Administration of the combination therapy composition to the target

[0300] A combination therapeutic composition (e.g., the solid compositions shown in Figures 5 and 6) containing a non-cannabinoid therapeutic compound and a cannabinoid compound is administered to a subject having or suspected to have a certain condition. After administration, the subject is characterized by at least partial remission of the condition. For example, the subject may have cancer, and treatment using the combination therapeutic composition disclosed herein can at least partially treat the cancer (e.g., reduce the size of the subject's solid tumor). In another example, the subject may have a CNS disease disclosed herein, and treatment using the combination therapeutic composition disclosed herein can at least partially treat the CNS disease. (Example 11) Combination therapy of cannabinoids and doxorubicin

[0301] A combination therapeutic composition containing cannabinoids and doxorubicin is administered to subjects receiving cancer treatment with doxorubicin. Following administration, the subjects are characterized by at least partial remission of their condition (e.g., reduction in the size of the subjects' solid tumors). Following administration, the subjects are further characterized by a reduction in cardiomyopathy via the mitochondrial pathway and by activation of, binding to, or otherwise interacting with endogenous cannabinoid receptors in the heart. Administration of the combination therapeutic composition containing cannabinoids and doxorubicin results in improved outcomes for patients. (Example 12) Combined administration of cannabinoids and ketamine

[0302] A combination therapeutic composition containing cannabinoids and ketamine is administered to subjects exhibiting symptoms of depression. Following administration, subjects are characterized by enhanced antidepressant characteristics and reduced or eliminated psychostimulant effects compared to ketamine administration alone. Following administration, subjects are characterized by reduced motor impairment and assistance in fear extinction in neural networks.

[0303] Other examples of co-administration of cannabinoids and ketamine are provided in the reference “Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects” (Sartim, et al Neuropharmacology 2021, 195, 108679), which is fully incorporated herein by reference. (Example 13) Combination therapy of cannabinoids and atorvastatin

[0304] A combination therapeutic composition containing a cannabinoid and atorvastatin is administered to subjects receiving treatment for high cholesterol with atorvastatin. Following administration, the subjects are characterized by at least a partial reduction in cholesterol levels. Following administration, the subjects are characterized by improved (e.g., reduced) cholesterol levels and neuroprotective effects with the administration of the combination therapeutic composition compared to individual doses of atorvastatin. (Example 14) Combination therapy of cannabinoids and fluvastatin

[0305] A combination therapeutic composition containing a cannabinoid and fluvastatin is administered to subjects receiving treatment for high cholesterol with fluvastatin. Following administration, the subjects are characterized by at least a partial reduction in cholesterol levels. Following administration, the subjects are characterized by improved (e.g., reduced) cholesterol levels and neuroprotective effects with the administration of the combination therapeutic composition compared to individual doses of fluvastatin. (Example 15) Concomitant administration of cannabinoids and dextromethorphan

[0306] A combination therapeutic composition containing a cannabinoid and dextromethorphan is administered to subjects receiving treatment for cough with dextromethorphan. Following administration, subjects are characterized by at least partial remission of cough. Following administration, subjects are characterized by reduced inflammation and enhanced hepatoprotection compared to individual administrations of dextromethorphan. (Example 16) Combined administration of cannabinoids and ibuprofen

[0307] A combination therapeutic composition containing a cannabinoid and ibuprofen is administered to subjects receiving treatment for pain and inflammation with ibuprofen. Following administration, subjects are characterized by at least partial remission of pain and inflammation. Following administration, subjects are characterized by reduced inflammation, reduced pain, and enhanced hepatoprotection compared to individual doses of ibuprofen. (Example 17) Combined administration of cannabinoids and acetaminophen

[0308] A combination therapeutic composition containing a cannabinoid and acetaminophen is administered to subjects receiving treatment for pain and inflammation with acetaminophen. Following administration, subjects are characterized by at least partial remission of pain and inflammation. Following administration, subjects are characterized by reduced inflammation, reduced pain, and enhanced hepatoprotection compared to individual doses of acetaminophen. (Example 18) Combined administration of cannabinoids and naproxen

[0309] A combination therapeutic composition containing a cannabinoid and naproxen is administered to subjects receiving treatment for pain and inflammation with naproxen. Following administration, subjects are characterized by at least partial remission of pain and inflammation. Following administration, subjects are characterized by reduced inflammation, reduced pain, and enhanced hepatoprotection compared to individual administrations of naproxen. (Example 19) Concomitant administration of cannabinoids and diazepam

[0310] A combination therapeutic composition containing a cannabinoid and diazepam is administered to subjects receiving treatment for anxiety and depression with diazepam. Following administration, the subjects are characterized by at least partial remission of anxiety and depression. After administration, the subjects are characterized by a synergistic anxiolytic effect of the cannabinoid and benzodiazepine combination, lower addictive potential, and protection of the subjects' liver and brain compared to diazepam alone. (Example 20) Concomitant administration of cannabinoids and alprazolam

[0311] A combination therapeutic composition containing a cannabinoid and alprazolam is administered to subjects receiving treatment for anxiety and depression with alprazolam. Following administration, the subjects are characterized by at least partial remission of anxiety and depression. After administration, the subjects are characterized by a synergistic anxiolytic effect of the cannabinoid and benzodiazepine combination, lower addictive potential, and protection of the subjects' liver and brain compared to individual doses of alprazolam. (Example 21) Concomitant administration of cannabinoids and clonazepam

[0312] A combination therapeutic composition containing a cannabinoid and clonazepam is administered to subjects receiving treatment for anxiety and depression with clonazepam. Following administration, the subjects are characterized by at least partial remission of anxiety and depression. After administration, the subjects are characterized by a synergistic anxiolytic effect of the cannabinoid and benzodiazepine combination, lower addictive potential, and protection of the subjects' liver and brain compared to clonazepam alone.

[0313] Preferred embodiments of the present invention have been shown and described herein, but it will be apparent to those skilled in the art that such embodiments are provided merely as examples. The present invention is not intended to be limited by any particular example provided herein. The present invention has been described with reference to the foregoing specification, but the descriptions and examples of embodiments herein are not intended to be construed as limiting. Hereinafter, those skilled in the art will come up with many variations, modifications, and substitutions without departing from the present invention. Furthermore, it will be understood that all aspects of the present invention are not limited to any particular figures, configurations, or relative proportions described herein, depending on a wide variety of conditions and variables. It should be understood that in carrying out the present invention, various substitutes may be used for the embodiments of the present invention described herein. Accordingly, the present invention is intended to encompass any such substitutes, modifications, variations, or equivalents. The following claims define the scope of the present invention, and the methods and structures within these claims, as well as their equivalents, are intended to be encompassed thereby.

Claims

1. 1. A composition comprising a cannabinoid compound and a non-cannabinoid therapeutic compound, The non-cannabinoid therapeutic compound may be Kyprolis, Epogen, Nplate, Vectibix, Blincyto, Corlanor, Evenity, Imlygic, Kanjinti, MVASI, Neupogen, Prolia, Repatha, Depakote, Gengraf, Kaletra, Leuplin, Mavyret, Oriahnn, Rinvoq, Survanta, Synthroid , ultane, venclexta, viekira, zemplar, Triumeq, Keytruda, Gardasil, Pneumovax, Ocrevus, Cyramza, doxorubicin, nano-derived liposomal doxorubicin, nano-derived liposomal taxanes, ketamine, statins, dextromethorphan, nonsteroidal anti-inflammatory drugs, benzodiazepines, and compositions selected from the group consisting of Tables 1-10.

2. 2. The composition of claim 1, wherein at least one of i) the cannabinoid compound and ii) the non-cannabinoid therapeutic compound is encapsulated.

3. The composition of claim 2 , wherein the cannabinoid compound and the non-cannabinoid therapeutic compound are encapsulated.

4. 4. The composition of claim 3, wherein the cannabinoid compound and the non-cannabinoid therapeutic compound are encapsulated in the same microcapsules among a plurality of microcapsules of the composition.

5. 4. The composition of claim 3, wherein the cannabinoid compound and the non-cannabinoid therapeutic compound are encapsulated in different microcapsules of a plurality of microcapsules of the composition.

6. The composition of claim 1 in a solid dosage form.

7. 2. The composition of claim 1, comprising a first unit dosage form comprising the cannabinoid compound and a second unit dosage form comprising the non-cannabinoid therapeutic compound, the first unit dosage form and the second unit dosage form being for sequential or simultaneous administration to a subject in need thereof.

8. A kit comprising the composition of any one of claims 1 to 7, further comprising instructions for administering the composition to a subject in need thereof.

9. 8. The composition of any one of claims 1 to 7 for use in a method comprising administering said composition to a subject in need thereof.

10. 1. A composition comprising a cannabinoid compound and a non-cannabinoid therapeutic compound, The non-cannabinoid therapeutic compound is Enbrel, Neulasta, Prolia, XGEVA, Aranesp, Sensipar / Mimpara, Avsola, Otezla, Parsabiv, AndroGel, Creon, Duopa, Humira, Imbruvica, Niaspan, Orilissa, Skyrizi, Synagis, Trilipix, Advair, Tivicay, Breo / Relvar Ellipta, Ventolin, Lamictal, Avodart, Flovent, Augmentin, Rotarix, Shingrix, Januvia, Janumet, Isentress, Bridion, NuvaRing, Simponi, Zetia / Vytorin, Herceptin, Avastin, Rituxan, Perjeta, Xolair, Actemra, Lucentis, Activase / TNKase, Esbriet, Lantus, Aubagio, Lovenox, Plavix, Myozyme, Toujeo, Dupixent, Fabrazyme, Trulicity, Humalog, Alimta, Cialis, Forteo, Humulin, Taltz, Basaglar, Cymbalta, Xarelto, Eylea, Mirena, Kogenate, Nexavar, Yasmin, Precose, Adalat, Aspirin Cardio, Betaseron, Tagrisso, Symbicort, Brilinta, Farxiga, Nexium, Imfinzi, Pulmicort, Crestor, Lynparza, Faslodex, Eliquis, Opdivo, Sprycel, Orencia SC, Yervoy, Orencia, Revlimid, Baraclude, Empliciti, Nulojix, Stelara, Remicade, Zytiga, Invega Sustenna, Darzalex, Prezista, Imbruvica, Opsumit, Prevnar 13, Lyrica, Ibrance, Lipitor, Xeljanz, Chantix, Sutent, Norvasc, Premarin, Gilenya, Cosent yx, Lucentis, Tasigna, Sandostatin, Gleevec, Afinitor, Galvus, Promacta, Tafinlar, Entyvio , Velcade, Leuprorelin, Azilva, Dexilant, Ninlaro, Genvoya, Truvada, Epclusa, Odefsey, Descovy, Harvoni, Atripla, Biktarvy, Letairis, Ranexa, Copaxone, Bendeka, Methylphenidate hydrochloride, ProAir A composition selected from the group consisting of HFA, Austedo, QVAR RediHaler, daptomycin, metoprolol succinate, sildenafil citrate, hypochlorous acid, doxorubicin, nano-derivative liposomal doxorubicin, nano-derivative liposomal taxanes, ketamine, statins, dextromethorphan, nonsteroidal anti-inflammatory drugs, and benzodiazepines.

11. 11. A kit comprising the composition of any one of claims 1 to 7 and 10, further comprising instructions for administering said composition to a subject in need thereof.

12. 11. The composition of any one of claims 1 to 7 and 10 for use in a method comprising administering said composition to a subject in need thereof.

13. 1. A composition comprising a cannabinoid compound and a non-cannabinoid therapeutic compound for use in a method comprising administering said composition to a subject in need thereof; The non-cannabinoid therapeutic compound may be Kyprolis, Epogen, Nplate, Vectibix, Blincyto, Corlanor, Evenity, Imlygic, Kanjinti, MVASI, Neupogen, Prolia, Repatha, Depakote, Gengraf, Kaletra, Leuplin, Mavyret, Oriahnn, Rinvoq, Survanta, Synthroid , ultane, venclexta, viekira, zemplar, Triumeq, Keytruda, Gardasil, Pneumovax, Ocrevus, Cyramza, doxorubicin, nano-derived liposomal doxorubicin, nano-derived liposomal taxanes, ketamine, statins, dextromethorphan, nonsteroidal anti-inflammatory drugs, benzodiazepines, and compositions selected from the group consisting of Tables 1-10.

14. 1. A composition comprising a cannabinoid compound and a non-cannabinoid therapeutic compound for use in a method comprising administering said composition to a subject in need thereof; The non-cannabinoid therapeutic compound is Enbrel, Neulasta, Prolia, XGEVA, Aranesp, Sensipar / Mimpara, Aranesp, Avsola, Otezla, Parsabiv, AndroGel, Creon, Duopa, Humira, Imbruvica, Niaspan, Orilissa, Skyrizi, Synagis, Trilipix, Advair, Tivicay, Breo / Relvar Ellipta, Ventolin, Lamictal, Avodart, Flovent, Augmentin, Rotarix, Shingrix, Januvia, Janumet, Isentress, Bridion, NuvaRing, Simponi, Zetia / Vytorin, Herceptin, Avastin, Rituxan, Perjeta, Xolair, Actemra, Lucentis, Activase / TNKase, Esbriet, Lantus, Aubagio, Lovenox, Plavix, Myozyme, Toujeo, Dupixent, Fabrazyme, Trulicity, Humalog, Alimta, Cialis, Forteo, Humulin, Taltz, Basaglar, Cymbalta, Xarelto, Eylea, Mirena, Kogenate, Nexavar, Yasmin, Precose, Adalat, Aspirin Cardio, Betaseron, Tagrisso, Symbicort, Brilinta, Farxiga, Nexium, Imfinzi, Pulmicort, Crestor, Lynparza, Faslodex, Eliquis, Opdivo, Sprycel, Orencia SC, Yervoy, Orencia, Revlimid, Baraclude, Empliciti, Nulojix, Stelara, Remicade, Zytiga, Xarelto, Invega Sustenna, Simponi, Darzalex, Prezista, Imbruvica, Opsumit, Prevnar13, Lyrica, Ibrance, Enbrel, Lipitor, Xeljanz, Chantix, Sutent, Norvasc, Premarin, Gilenya, C osetyx, Lucentis, Tasigna, Sandostatin, Gleevec, Afinitor, Galvus, Promacta, Tafinlar, Enty vio, Velcade, Leuprorelin, Azilva, Dexilant, Ninlaro, Genvoya, Truvada, Epclusa, Odefsey, De scovy, Harvoni, Atripla, Biktarvy, Letairis, Ranexa, Copaxone, Bendeka, Methylphenidate Hydrochloride, ProAir A composition selected from the group consisting of HFA, Austedo, methylphenidate hydrochloride, QVAR RediHaler, daptomycin, metoprolol succinate, sildenafil citrate, hypochlorous acid, doxorubicin, nano-derivative liposomal doxorubicin, nano-derivative liposomal taxanes, ketamine, statins, dextromethorphan, nonsteroidal anti-inflammatory drugs, and benzodiazepines.